Harry is the Founder of 20VC. Our mission is to leverage our media company to build products that allow us to be the best investors in the world. <\/p>","country":"gb","companies":[],"created_at":"2025-04-10T04:43:51.000000Z"},{"id":130,"name":"Antoine Papiernik","title":"Chairman & Managing Partner","photo":{"id":1891,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1891\/Headshot-Creator-for-Website---2025-07-22T081350.737.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1891\/conversions\/Headshot-Creator-for-Website---2025-07-22T081350.737-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1891\/conversions\/Headshot-Creator-for-Website---2025-07-22T081350.737-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1891\/conversions\/Headshot-Creator-for-Website---2025-07-22T081350.737-large.webp"},"category":"investors_strategics","roles":["F","I","P"],"company_name":"Sofinnova Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/antoine-papiernik-06075610\/","biography":"
Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997.<\/p>\r\n
“Life Sciences investing is not just about recognizing good science,” Papiernik says, “it’s about people — learning how to interact with co-investors, limited partners, and entrepreneurs. Listening, discerning, negotiating, and finding common interests.”<\/p>\r\n
When you find the right people to invest in, he adds, “you can bank on them more often than you can predict how the science is going to turn out.” He looks for entrepreneurs with the nimbleness to adapt, “even if that means making a major shift from where one starts out on the journey.”<\/p>\r\n
Antoine actively invests for our Capital Funds. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), and Movetis (sold to Shire). Trade sale success stories include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka).<\/p>\r\n
He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, May Health, Highlife and Inspirna (formerly Rgenix).<\/p>\r\n
Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.<\/p>","country":"","companies":[],"created_at":"2025-04-17T18:40:37.000000Z"},{"id":146,"name":"Dirk Barten","title":"SVP and GM, Europe","photo":{"id":1527,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1527\/Headshot-Creator-for-Website-(83).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1527\/conversions\/Headshot-Creator-for-Website-(83)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1527\/conversions\/Headshot-Creator-for-Website-(83)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1527\/conversions\/Headshot-Creator-for-Website-(83)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dirkbarten\/","biography":"
Dirk Barten is senior vice president and general manager, Europe commercial and marketing at Intuitive.<\/span><\/p>\r\n Since joining the company in 2016, led the expansion of Germany’s top integrated delivery networks.<\/span><\/p>\r\n Prior to Intuitive, Barten was managing director at Schölly Fiberoptic GmbH in Denzlingen. Before that, he worked for General Electric Healthcare GmbH, holding several positions including integration manager for the acquisition of medical technology companies. In addition, Barten previously was European product manager at Elekta Instrument GmbH in Germany and Stockholm. Contrarian entrepreneur Carey Smith founded Big Ass Fans in 1999 and led the company for 18 years. While other founders made and lost their fortunes, Carey’s business practices led to sustained, rapid growth averaging 40% annually. Inc. Magazine<\/em> ranked Big Ass Fans among America’s fastest-growing private companies for 11 years straight — a feat achieved by only 34 others.<\/p>\r\n Carey has earned national recognition for his common-sense business philosophies, such as selling direct, investing in silver-platter customer service and paying employees more than 30% above the U.S. average. Inc. named him “Economy Hero” in 2011 for refusing to lay off employees during the Great Recession.<\/p>\r\n By 2017, Carey had grown Big Ass Fans from six employees to more than a thousand and nearly $300 million in annual sales. He did so without investors, a rarity in a society that glamorizes venture capital and quick exits. That year, he sold the company for $500 million with $50 million going right into employees’ pockets.<\/p>\r\n Following the sale, Carey founded the investment firm Unorthodox Ventures. He assembled a staff experienced in everything from engineering and supply chain to marketing and customer service with the goal of providing founders far more than money. The firm has invested in more than a dozen businesses and given advice and assistance to hundreds of founders without charging a dime.<\/p>","country":"","companies":[],"created_at":"2025-06-03T16:33:13.000000Z"},{"id":342,"name":"Amira Romani","title":"Senior Vice President Innovation Strategy and Ecosystem","photo":{"id":1841,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1841\/amira-romani-siemens-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1841\/conversions\/amira-romani-siemens-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1841\/conversions\/amira-romani-siemens-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1841\/conversions\/amira-romani-siemens-europe-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Siemens Healthineers","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amira-romani-23ab371\/","biography":" Amira Romani is Head of Innovation Strategy at Siemens Healthineers and leads the global innovation ecosystem Siemens Healthineers SHIFT. In this role, she drives international collaboration with partners from research, industry, start-ups, and policy on key topics such as digital transformation, sustainability, and health equity. She also initiates and supports strategic consortium projects—such as improving stroke care in Europe—to foster impactful innovation in healthcare.<\/p>","country":"","companies":[],"created_at":"2025-07-14T20:17:19.000000Z"},{"id":214,"name":"Josh Makower","title":"Director & Co-Founder, Stanford Byers Center for Biodesign","photo":{"id":1654,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1654\/josh-makower-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1654\/conversions\/josh-makower-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1654\/conversions\/josh-makower-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1654\/conversions\/josh-makower-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Venture Partner, Sofinnova Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/josh-makower\/","biography":" Medical & Health Technology Innovator, Entrepreneur, Inventor, Venture Capitalist<\/p>","country":"","companies":[],"created_at":"2025-06-18T23:17:25.000000Z"},{"id":366,"name":"Andrew Chung","title":"Founder and Managing Partner","photo":{"id":1894,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1894\/andrew-chung-1955-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1894\/conversions\/andrew-chung-1955-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1894\/conversions\/andrew-chung-1955-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1894\/conversions\/andrew-chung-1955-europe-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"1955 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/achung\/","biography":" Andrew has been a tech investor and entrepreneur for over 20 years with rare experience and success investing in sustainability and health technology. He was involved with 8 unicorns in world-positive sectors while at Khosla Ventures and Lightspeed Ventures that have created over $30 billion of market value. He founded 1955 Capital to invest in revolutionary technologies to solve the greatest global challenges of our time. 1955 was the largest venture capital firm debut in Q1 2016 and focuses on sustainability (energy, food, agriculture), education, health, and other emerging technologies.<\/p>\r\n Prior to launching 1955 Capital, Andrew was a general partner at Khosla Ventures<\/strong><\/a>, a venture capital firm with over $15 billion under management and the world’s largest sustainable technology venture portfolio. Andrew joined Khosla in 2011 as one of six partners leading the firm. He served as board director or helped advise more than 20 Khosla portfolio companies, including:<\/p>\r\n Ambri<\/strong><\/a> (grid storage)<\/p>\r\n<\/li>\r\n BioConsortia<\/strong><\/a> (agriculture)<\/p>\r\n<\/li>\r\n Calera<\/strong><\/a> (carbon to building materials)<\/p>\r\n<\/li>\r\n Cogenra (solar) [acq. by SPWR]<\/p>\r\n<\/li>\r\n EcoMotors (automotive)<\/p>\r\n<\/li>\r\n Impossible Foods<\/strong><\/a> (alternative proteins)<\/p>\r\n<\/li>\r\n Lanzatech<\/strong><\/a> (carbon to bioenergy) [LNZA]<\/p>\r\n<\/li>\r\n LS9 (bioenergy) [acq. by REGI]<\/p>\r\n<\/li>\r\n Quantumscape<\/strong><\/a> (energy storage) [QS]<\/p>\r\n<\/li>\r\n Wattpad<\/strong><\/a> (education) [acq. by Naver]<\/p>\r\n<\/li>\r\n<\/ul>\r\n While at Khosla, Andrew also led the firm’s Asia activities and speaks fluent Mandarin and Cantonese Chinese. He worked with many portfolio companies to develop models for cross-border collaboration to address tough environmental challenges facing the developing world. He served as an advisor to the 2014 US-China trade mission led by the Secretaries of Commerce & Energy.<\/p>\r\n Prior to Khosla, Andrew was at Lightspeed Venture Partners<\/strong><\/a>, a global venture capital platform with $18 billion under management, and helped build the firm’s practice areas in cleantech, education and genomics that invested early in<\/p>\r\n Natera<\/strong><\/a> (genomics) [NTRA]<\/p>\r\n<\/li>\r\n Nest Labs<\/strong><\/a> (IOT) [acq. by GOOG]<\/p>\r\n<\/li>\r\n Orbis<\/strong><\/a> (education) [acq. by LOPE]<\/p>\r\n<\/li>\r\n Personalis<\/strong><\/a> (genomics) [PSNL]<\/p>\r\n<\/li>\r\n Quantumscape<\/strong><\/a> (energy storage) [QS]<\/p>\r\n<\/li>\r\n SolarEdge<\/strong><\/a> (solar) [SEDG]<\/p>\r\n<\/li>\r\n Solazyme (bioenergy) [SZYM]<\/p>\r\n<\/li>\r\n<\/ul>\r\n As a thought leader in sustainable technology and U.S.-Asia collaboration, Andrew served on a White House roundtable on advanced manufacturing during the Obama Administration and has advised global leaders on energy policy. He has given talks on the future of food and energy, moonshot entrepreneurship, translating university research, ESG investing, and U.S.-Asia relations at numerous global conferences. Andrew was the Founding Chair of the Cleantech Board for The Indus Entrepreneurs<\/strong><\/a> group (TiE), the largest global organization focused on fostering entrepreneurship, and he is a long-time advisor to the Cleantech Open<\/strong><\/a> (CTO), the largest cleantech accelerator in the world. He is also on the Advisory Board of Future Food-Tech<\/strong><\/a>, world-leading event series focusing on the most disruptive technologies transforming our food system. He has also been a guest lecturer at Harvard, Wharton, Stanford, MIT, Tsinghua (\u6e05\u534e\u5927\u5b66), Peking University (\u5317\u4eac\u5927\u5b66), and the Paulson Institute.<\/p>\r\n Previously, Andrew was an investor at Bain Capital and TL Ventures, where he supported buyout and venture investments in healthcare, software and semiconductors. Prior to that, he was a management consultant with Bain & Company in Greater China, where he worked with clients in energy, private equity, retail, and logistics. Earlier in his career, Andrew co-founded UberWorks [acq. by NWKC], an e-commerce platform incubated at Trilogy.<\/p>\r\n Andrew holds a BA in Applied Mathematics from Harvard University, graduating Phi Beta Kappa with honors as a Detur Prize recipient, and an MBA from the Wharton School of Business. Andrew currently serves on the Dean’s Advisory Cabinet at the Harvard John A. Paulson School for Engineering and Applied Sciences (SEAS)<\/strong><\/a>, where he sits on the Harvard Life Sciences & Innovation Task Force, and served on the Advisory Board for the Wharton Initiative for Global Environmental Leadership (IGEL)<\/strong><\/a>.<\/p>\r\n Andrew is an avid musician and nearly pursued a singing career after winning a national Chinese singing contest and becoming a finalist in Hong Kong Idol. He has performed as a vocalist and conductor at Lincoln Center, the Kennedy Center, the Shanghai Conservatory, and off-Broadway. In addition to music, Andrew enjoys photography, ski mountaineering, traveling and baseball. He is an IFSA L100 certified ski coach, supporting his 11-year-old Aria to win the 2024 North American Jr. Freeride Championship.<\/p>","country":"","companies":[],"created_at":"2025-07-22T18:45:49.000000Z"},{"id":97,"name":"Murielle Thinard McLane","title":"President and Managing Partner","photo":{"id":1506,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1506\/Headshot-Creator-for-Website-(65).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1506\/conversions\/Headshot-Creator-for-Website-(65)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1506\/conversions\/Headshot-Creator-for-Website-(65)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1506\/conversions\/Headshot-Creator-for-Website-(65)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/murielle-thinard-mclane\/","biography":" \uf0a7 Seasoned healthcare executive with successful track record at establishing strategy, securing resources and executing both in the corporate and venture backed world Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:16:34.000000Z"},{"id":187,"name":"Caroline Gaynor","title":"Partner","photo":{"id":1499,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1499\/Headshot-Creator-for-Website-(57).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1499\/conversions\/Headshot-Creator-for-Website-(57)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1499\/conversions\/Headshot-Creator-for-Website-(57)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1499\/conversions\/Headshot-Creator-for-Website-(57)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Lightstone Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/cgaynor\/","biography":" Caroline Gaynor is a Partner of Lightstone Ventures and focuses on new investments in the biopharmaceutical and medical device sectors out of the firm’s Dublin office. She currently serves as a board director for Parvalis Therapeutics, ProVerum, Carrick Therapeutics and FIRE-1 and as board observer for Volta Medical and Cerevance. She also previously served on the board of ALX Oncology. She is a council member of the Irish Venture Capital Association and a member of the BioInnovate Ireland Board of advisors.<\/p>\r\n Caroline joined Lightstone Ventures in 2017, bringing 15 years’ operational experience in the pharmaceutical industry and early stage medtech companies. Caroline spent 9 years at Bayer Healthcare, most recently serving on the board of senior management of Bayer Ltd. Ireland as head of market access, pricing and reimbursement. During her time in pharma she held a number of operational roles, predominantly focused on oncology, such as product management, strategic marketing, business development and regulatory\/clinical affairs. Prior to Lightstone, and following completion of her BioInnovate fellowship in 2013, she co-led R&D on a device targeting Acute Pancreatitis and was subsequently involved in early pre-clinical, strategic clinical and commercial development at Vetex Medical.<\/p>\r\n In 2002 She received her degree in Pharmacy from Trinity College Dublin and subsequently went on to receive an M.Sc in Pharmaceutical Medicine in 2010.<\/p>","country":"","companies":[],"created_at":"2025-06-02T18:17:05.000000Z"},{"id":237,"name":"Samuel Levy","title":"Founding Partner","photo":{"id":1657,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1657\/Samuel-Levy-lauxera-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1657\/conversions\/Samuel-Levy-lauxera-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1657\/conversions\/Samuel-Levy-lauxera-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1657\/conversions\/Samuel-Levy-lauxera-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Lauxera Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/samuel-levy-543b001\/","biography":" I invest in commercial-stage health technology businesses at Lauxera Capital Partners, a firm I created in 2020. Previously, I co-founded Allurion Technologies during my second year of medical school. Over ten years, along with my partners, I built a fully-integrated, global medical device company from the idea stage through commercialization in more than 30 countries. I started my career as a member of McKinsey and Company's New York Office and Pharmaceutical and Medical Products Practice.<\/p>","country":"fr","companies":[],"created_at":"2025-06-27T16:52:37.000000Z"},{"id":136,"name":"Celia Hart","title":"General Partner","photo":{"id":1500,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1500\/Headshot-Creator-for-Website-(58).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1500\/conversions\/Headshot-Creator-for-Website-(58)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1500\/conversions\/Headshot-Creator-for-Website-(58)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1500\/conversions\/Headshot-Creator-for-Website-(58)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Supernova Invest","linkedin_profile":"https:\/\/www.linkedin.com\/in\/hartcelia\/","biography":" Experienced deeptech investor in Life Sciences (+15 years) with a strong operational experience in the biotech Industry (Cambridge Antibody Technology\/Medimmune) and a solid academic education (Ph.D. Chemistry\/Oxford). Strong interest in companies developping life changing products and driven by outstanding entrepreneurs<\/p>","country":"","companies":[],"created_at":"2025-04-24T15:05:51.000000Z"},{"id":135,"name":"Brent Ahrens","title":"General Partner","photo":{"id":1525,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1525\/Headshot-Creator-for-Website-(81).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1525\/conversions\/Headshot-Creator-for-Website-(81)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1525\/conversions\/Headshot-Creator-for-Website-(81)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1525\/conversions\/Headshot-Creator-for-Website-(81)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Canaan Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brent-ahrens-60154\/","biography":" Brent leads investments in an array of healthcare companies, with a focus on biopharma and medtech. Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit. Brent earned an MBA from the Tuck School of Business at Dartmouth College after graduating with a B.S. and M.S. in Mechanical Engineering from the University of Dayton.<\/p>","country":"","companies":[],"created_at":"2025-04-22T15:20:16.000000Z"},{"id":139,"name":"Thom Rasche","title":"Managing Partner","photo":{"id":1623,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1623\/thom-rasche-earlybird-europe-(2).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1623\/conversions\/thom-rasche-earlybird-europe-(2)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1623\/conversions\/thom-rasche-earlybird-europe-(2)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1623\/conversions\/thom-rasche-earlybird-europe-(2)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Earlybird Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/thom-rasche\/","biography":" Experienced executive in Healthcare with operational and financial expertise Managing partner, president and co-founder at Asabys. Josep currently serves on the board of directors of Anaconda, Cara Care, Inbrain Neuroelectronics, Medasense, Medlumics and Psious.<\/strong><\/p>\r\n Formerly, Josep co-founded Ysios Capital (2008-2018) where he was the partner in charge of Health Technology investments, investing in a total of 9 companies in the areas of medtech and digital health in Europe and in the US. Previously, Josep held positions in the pharmaceutical and home-healthcare industries as Corporate Development Director at Almirall and General Manager of DomusVi. Josep started his career in Cuatrecasas, KPMG and Eurohold.<\/p>\r\n Josep has a Degree in Law by the Universitat Pompeu Fabra, a Master of Laws (LL.M.) from the University of Michigan Law School and also an MBA from IESE Business School.<\/p>","country":"","companies":[],"created_at":"2025-07-14T05:35:07.000000Z"},{"id":361,"name":"Erin McEachren","title":"Vice President & General Manager, Enabling Technologies: Cranial and Spinal Technologies","photo":{"id":1882,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1882\/erin-mceachren-medtronic-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1882\/conversions\/erin-mceachren-medtronic-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1882\/conversions\/erin-mceachren-medtronic-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1882\/conversions\/erin-mceachren-medtronic-europe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/erinmceachren\/","biography":" Erin is dynamic and proven healthcare leader that has experience in medical device sales, marketing, strategic planning, commercialization and business development. She is currently Vice President, International, at Medtronic executing all aspects of commercial strategy. Erin excels at working cross functionally and across different geographies. She manages the strategy for innovative portfolio with capital, robotics, navigation, imaging, implant and disposables. Medical technology investor looking for teams & products that are looking to change healthcare for the better. Experienced executive with a passion for creating and marketing life changing products and delivering them to customers.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:15:23.000000Z"},{"id":112,"name":"Dan Sheehan","title":"Vice President, Venture Capital","photo":{"id":1509,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1509\/Headshot-Creator-for-Website-(68).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1509\/conversions\/Headshot-Creator-for-Website-(68)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1509\/conversions\/Headshot-Creator-for-Website-(68)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1509\/conversions\/Headshot-Creator-for-Website-(68)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dan-sheehan-802058247\/","biography":" Dan manages the activities of Medtronic Ventures, Medtronic’s Corporate Venture Capital investment group. He began Corporate Venture investing in 2008, and since that time his teams have made investments in over 50 healthcare and medical technology companies. Dan has served on several portfolio company boards and is passionate about working with managers and investors in emerging companies. Prior to Medtronic, he was a General Partner with Affinity Capital Management, a healthcare-oriented venture capital firm. He has also managed the business development and strategic marketing efforts for Steris Corporation. He is a graduate of Fordham University and Columbia Business School.<\/p>","country":"us","companies":[],"created_at":"2025-04-09T23:40:45.000000Z"},{"id":93,"name":"Craig Smith","title":"Senior Director, Venture Capital","photo":{"id":1510,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1510\/Headshot-Creator-for-Website-(69).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1510\/conversions\/Headshot-Creator-for-Website-(69)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1510\/conversions\/Headshot-Creator-for-Website-(69)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1510\/conversions\/Headshot-Creator-for-Website-(69)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/craig-smith-4a05096\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-10T05:35:57.000000Z"},{"id":128,"name":"Jean Chaoui","title":"Vice President of Clinical Applications and Solutions, Digital, Robotics and Enabling Technologies","photo":{"id":1461,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1461\/jean-chaoui-stryker-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1461\/conversions\/jean-chaoui-stryker-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1461\/conversions\/jean-chaoui-stryker-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1461\/conversions\/jean-chaoui-stryker-europe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Stryker","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeanchaoui\/","biography":" Understanding Physicians\/Surgeons\/Customers needs and defining cutting edge technology pipeline solutions and Business Strategy. CEO and founder of CryoTherapeutics, a company focused on treatment of heart disease, and Partner with Earlybird Venture Capital, Health Fund, a leading life sciences investor serving European early stage innovation.<\/p>","country":"","companies":[],"created_at":"2025-05-28T17:31:16.000000Z"},{"id":486,"name":"Charles Taylor","title":"Moncrief, Jr., Chair in Computational Medicine; Professor, Department of Internal Medicine & Oden Institute for Computational Engineering and Sciences; Director, Center for Computational Medicine","photo":{"id":2135,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/2135\/Headshot-Creator-for-Website---2025-08-22T120105.811.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/2135\/conversions\/Headshot-Creator-for-Website---2025-08-22T120105.811-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/2135\/conversions\/Headshot-Creator-for-Website---2025-08-22T120105.811-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/2135\/conversions\/Headshot-Creator-for-Website---2025-08-22T120105.811-large.webp"},"category":"investors_strategics","roles":[],"company_name":"UT Austin","linkedin_profile":"https:\/\/www.linkedin.com\/in\/charles-taylor-01765421\/","biography":" Dr. Taylor is the W.A. “Tex” Moncrief, Jr., Chair in Computational Medicine, Professor, in the Department of Internal Medicine and the Oden Institute for Computational Engineering and Sciences and Director of the Center for Computational Medicine at the University of Texas, Austin. <\/span><\/p>\r\n Dr. Taylor is also a Founder and Member of the Board of Directors of HeartFlow Inc. He was Chief Technology Officer at HeartFlow from 2010 to 2021 and then Chief Scientific Officer from 2021 to 2023. Dr. Taylor is also the Chairman of Ebenbuild, GmBh. Prior to HeartFlow, he was an Associate Professor in the Departments of Bioengineering and Surgery at Stanford University with courtesy faculty appointments in the Departments of Mechanical Engineering, Radiology and Pediatrics. He is internationally recognized for his pioneering work over the last 30 years in combining computer simulation methods with medical imaging data for patient-specific modeling of blood flow to aid in the diagnosis and treatment of cardiovascular disease. Dr. Taylor has published over 450 peer-reviewed journal and conference papers and has more than 300 issued patents worldwide. He received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering and M.S. degree in Mathematics from Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University. He received the “Young Investigator in Computational Mechanics Award” in 2002 from the International Association for Computational Mechanics and the “R.H. Gallagher Young Investigator in Computational Mechanics” from the United States Association for Computational Mechanics in 2003. In 2007 he was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2019 he received the Davies Medal for Engineering Achievement from Rensselaer Polytechnic Institute. In 2024 Dr. Taylor was elected into the National Academy of Engineering. Actively investing out of Endeavour Medtech Growth II, focusing on growth stage medical device and digital health companies in Europe and the US.<\/p>\r\n Specialities:<\/p>\r\n He is widely sought after for his strategic insight and knowledge of structuring M&A transactions and currently serves on the boards of several healthcare companies, including Shockwave Medical (NASDAQ: SWAV), Avail Medsystems, RefleXion Medical, Tissium and Neptune Medical.<\/p>","country":"","companies":[],"created_at":"2025-07-16T06:15:26.000000Z"},{"id":351,"name":"Dennis McWilliams","title":"Partner","photo":{"id":1866,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1866\/Dennis-McWilliams-sante-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1866\/conversions\/Dennis-McWilliams-sante-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1866\/conversions\/Dennis-McWilliams-sante-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1866\/conversions\/Dennis-McWilliams-sante-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SANT\u00c9","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dennismcwilliams\/","biography":" Janke Dittmer joined Gilde in 2011 as a Partner. He led Gilde’s investment in Definiens (acquired by AZ), Sapiens (acquired by Medtronic), Volta Medical, Big Health, FIRE1, Lumeon and Nyxoah (IPO on NASDAQ) and was involved in several other investments including Spire Health, Withings, NightBalance and Stat Dx. He currently represents Gilde on the board of Volta Medical, Big Health, FIRE1 and Lumeon. He served on the supervisory board of Definiens and Sapiens until trade sale and as Vice-chairman of Nyxoah until NASDAQ IPO.<\/p>\r\n Prior to joining, he was a Venture General Manager and Head of Business Development & Strategy within Philips’ Corporate Venturing unit in Healthcare. On top of shaping the strategy, he was responsible for selecting new investment opportunities. He also started and lead two ventures in the fields of cardiology and sepsis.<\/p>\r\n He served as an Engagement Manager at McKinsey & Company advising leading High Tech companies on strategies for growth and strategic marketing.<\/p>\r\n Prior to this, he cofounded a Nanotech company in the Silicon Valley after serving as a Fellow at the Lawrence Berkeley National Lab. He earned a PhD in Physics from the University of Cambridge in the UK and was a Post-Doc in Nanotechnology at the University of California, Berkeley.<\/p>\r\n He is a founder and former healthcare chairman of the International Venture Club, serves on the VC council of Invest Europe and has advised the European Commission on innovation policy.<\/p>\r\n He is a German citizen based in Gilde’s Utrecht office. At Gilde Healthcare he is focusing on Digital and Home Health, MedTech, Diagnostics and Lifescience Tools investments.<\/p>","country":"nl","companies":[],"created_at":"2025-06-09T00:58:54.000000Z"},{"id":169,"name":"Nathan Harrington","title":"Managing Partner, Philips Ventures","photo":{"id":1554,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1554\/Headshot-Creator-for-Website---2025-06-13T181941.763.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1554\/conversions\/Headshot-Creator-for-Website---2025-06-13T181941.763-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1554\/conversions\/Headshot-Creator-for-Website---2025-06-13T181941.763-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1554\/conversions\/Headshot-Creator-for-Website---2025-06-13T181941.763-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Philips","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nateharrington\/","biography":" Nate Harrington joined Philips in 2011 and is a Managing Partner at Philips Corporate Ventures, I specialize in identifying, funding, and scaling transformative healthcare and technology solutions. With 20+ years of experience in private investments, I have led and advised on 30+ successful investments, collectively exceeding $1 billion in deal value across the USA, Europe, Asia, and Africa. Mukul Mohanty is a private equity\/venture capital investor, deal specialist, and a seasoned fundraiser. I am passionate about improving physical, mental, and emotional human health through innovation. As Managing Partner and Shareholder at TVM Capital Life Science (TVM), I drive the firm’s global venture capital strategy in the Life Sciences sector. Since joining TVM in October 2000, I have built one of the longest active tenures in European venture capital, successfully managing and overseeing more than 50 investments. Over 20 years of international Venture Capital experience. I co-founded and led two of the most active pan-European Venture firms, investing in a variety of geographies and different sectors - mainly Digital, Cleantech\/Deep Tech and Healthcare\/LIfe Sciences - and generated several successful exits as trade sales or IPOs. Viresh Thakerar is an excellent leader with the ability to drive, develop and motivate a team to deliver groundbreaking results. He is confident individual and takes a “hands on” approach to and possesses a “can-do” attitude. He is a lateral thinker and has the ability to facilitate and develop and implement ideas to an effective end. He has a pragmatic approach to problem solving and is motivated by delivering tangible value. <\/p>\r\n Viresh specializes in Life Sciences Operations, whether it be in Pharma, Devices or CROs, he has a thorough understanding of the sector and what it takes to be operationally successful.<\/p>","country":"gb","companies":[],"created_at":"2025-06-20T22:45:23.000000Z"},{"id":208,"name":"Vishal Gulati","title":"Founder and Managing Partner","photo":{"id":1649,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1649\/Headshot-Creator-for-Website---2025-06-25T133819.257.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1649\/conversions\/Headshot-Creator-for-Website---2025-06-25T133819.257-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1649\/conversions\/Headshot-Creator-for-Website---2025-06-25T133819.257-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1649\/conversions\/Headshot-Creator-for-Website---2025-06-25T133819.257-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Recode Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/healthtechvc\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:06:25.000000Z"},{"id":333,"name":"William Dai","title":"Founding Managing Partner","photo":{"id":1890,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1890\/Headshot-Creator-for-Website---2025-07-22T080949.204.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1890\/conversions\/Headshot-Creator-for-Website---2025-07-22T080949.204-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1890\/conversions\/Headshot-Creator-for-Website---2025-07-22T080949.204-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1890\/conversions\/Headshot-Creator-for-Website---2025-07-22T080949.204-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"ShangBay Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/william-dai-65402419\/","biography":" Experienced Founding Partner with a demonstrated history of working in the venture capital and private equity industry. Skilled in Business Planning, Investor Relations, Corporate Finance, Business Development, and Strategic Planning. Strong entrepreneurship professional with a MBA focused in Finance from Michigan State University - The Eli Broad Graduate School of Management<\/p>","country":"","companies":[],"created_at":"2025-07-14T04:46:24.000000Z"},{"id":216,"name":"Michael Wasserman","title":"Partner & Chief Operating Officer","photo":{"id":1651,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1651\/Headshot-Creator-for-Website---2025-06-26T033635.047.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1651\/conversions\/Headshot-Creator-for-Website---2025-06-26T033635.047-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1651\/conversions\/Headshot-Creator-for-Website---2025-06-26T033635.047-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1651\/conversions\/Headshot-Creator-for-Website---2025-06-26T033635.047-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Elevage Medical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/michael-wasserman-a507493\/","biography":" Michael Wasserman, Ph.D. is a Partner and COO of Elevage. Michael has over 30 years of experience in healthcare as a scientist, entrepreneur, executive, and investor. Prior to Elevage, Michael served as Managing Partner of Maverix Private Equity. Michael spent 17 years at H.I.G. Capital, a diversified private equity firm with over $60 billion in assets. As a Managing Director of H.I.G.’s BioHealth platform, Michael\u202fsourced, executed, and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael worked closely with management teams and portfolio companies in key areas such as R&D, product development, market access, commercial and corporate strategy, equity and debt financing and achieving liquidity through M&A or IPO. Michael has served on the boards of numerous growth stage business including HyperBranch Medical Technologies (Stryker), NeuWave Medical (Johnson & Johnson), VertiFlex (Boston Scientific), amongst others.<\/p>\r\n Michael has also founded, held prominent operating roles, and sold several private healthcare businesses. Earlier in his career, Michael worked directly for, or as a consultant to, emerging technology businesses, and in the corporate finance, pharmaceutical and clinical research industries.<\/p>\r\n Michael is a member of the Board of Trustees for the Holland Bloorview Kids Rehabilitation Hospital. He is also on the Board of Toronto Innovation Acceleration Partners (TIAP), where he chairs the Investment Committee, the Board of ORT Canada, the Faculty of Science Advisory Board at McGill University, and is a Member of The Board of Trustees Research Committee at The Center for Addiction and Mental Health.<\/p>\r\n Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology and Neuroscience from the University of Toronto.<\/p>","country":"","companies":[],"created_at":"2025-06-19T21:30:56.000000Z"},{"id":106,"name":"Roberta Ferrari","title":"Managing Director","photo":{"id":1530,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1530\/Headshot-Creator-for-Website-(87).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1530\/conversions\/Headshot-Creator-for-Website-(87)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1530\/conversions\/Headshot-Creator-for-Website-(87)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1530\/conversions\/Headshot-Creator-for-Website-(87)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"EQT Group","linkedin_profile":"https:\/\/www.linkedin.com\/in\/roberta-ferrari-aa294bb\/","biography":" Roberta Ferrari is a Managing Director in the EQT Life Sciences team. Prior to joining EQT Life Sciences team, Roberta worked for 10 years as a Senior Investment Manager at Sony Innovation Fund in London, UK looking after digital health investments across EU and Middle East. Prior to Sony, Roberta was a Senior Consultant at Deloitte in Milan, Italy.<\/p>\r\n Roberta holds a MSc (Hons) and BSc In Industrial and Managerial Engineering, both from the University of Brescia (Italy). Roberta also studied Managerial Finance at the LSE and Venture Capital Programme at University of Oxford, UK.<\/p>","country":"gb","companies":[],"created_at":"2025-04-09T23:35:40.000000Z"},{"id":91,"name":"C David Adair","title":"Founder and Managing Partner","photo":{"id":1529,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1529\/Headshot-Creator-for-Website-(86).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1529\/conversions\/Headshot-Creator-for-Website-(86)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1529\/conversions\/Headshot-Creator-for-Website-(86)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1529\/conversions\/Headshot-Creator-for-Website-(86)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Solas BioVentures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/cdavidmugsyadair\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-07-13T07:27:22.000000Z"},{"id":224,"name":"Andreas Wuepper","title":"Managing Director","photo":{"id":1653,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1653\/Headshot-Creator-for-Website---2025-06-26T034112.418.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1653\/conversions\/Headshot-Creator-for-Website---2025-06-26T034112.418-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1653\/conversions\/Headshot-Creator-for-Website---2025-06-26T034112.418-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1653\/conversions\/Headshot-Creator-for-Website---2025-06-26T034112.418-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Fresenius Medical Care Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/andreas-wuepper\/","biography":" With an educational background both in life science and finance, and based on over 20 years of experience in the medical device industry, I am responsible for deal execution and management of portfolio companies at the corporate venture fund of Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure.<\/p>","country":"","companies":[],"created_at":"2025-06-20T22:58:31.000000Z"},{"id":218,"name":"Luc Marengere","title":"Managing Partner","photo":{"id":1892,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1892\/Headshot-Creator-for-Website---2025-07-22T081519.700.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1892\/conversions\/Headshot-Creator-for-Website---2025-07-22T081519.700-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1892\/conversions\/Headshot-Creator-for-Website---2025-07-22T081519.700-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1892\/conversions\/Headshot-Creator-for-Website---2025-07-22T081519.700-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"TVM Capital Life Science","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-luc-marengere-74b7865b\/","biography":" Luc joined TVM Partners in 2012. He is responsible for TVM Partners overall investment strategy and global fund operations.<\/p>\r\n Luc has more than 25 years of venture capital experience. He is a key driver of the investment strategy for TVM LSI I and TVM LSI II Funds. He is a Director on the Boards of late-stage company Panthera Dental, Egg Medical, Kent Imaging, Emovi and Access Vascular as well as early-stage companies Vespina, Occellaris and Auricula. In addition, Luc was a Director on the Board of NASDAQ listed Acer Therapeutics (sold to Zevra Tharapeutics) and Colucid Pharma Inc. (sold to Eli Lilly for US$960M) as well as privately held Aurka Pharma Inc. (sold to Eli Lilly for US$575M; total value includes upfront plus CVRs) and Acanthas Pharma (sold to Eli Lilly for US$430M; total value includes upfront plus CVRs).<\/p>\r\n Luc brought a significant track record to TVM given his experience as a venture capitalist. Notable deals during Luc‘s tenure as Managing Partner at Toronto-based VG Partners where he founded the life science investment practice include Cytochroma Inc. (sold to Opko for US$400M); VisualSonics (sold to Sonosite for US$75M), CITA Neuropharma (sold to Vernalis Plc for US$85M) and Trillium Therapeutics (sold to Pfizer for US$2.2B). Prior to joining VG Partners, Luc focused on venture investments in the life science sector while at Montreal-based Caisse De Depot (CDP) as well as MDS Capital and MedTech Partners.<\/p>\r\n Prior to his venture capital career, he conducted commercially oriented research in the fields of immunology and oncology at Amgen. Luc holds a Ph.D. from University of Toronto (Medical Biophysics and Molecular Genetics), a Master’s degree from Queen’s University (Biochemistry) and a degree from University of Ottawa (Bachelor’s degree, Biochemistry, Magna Cum Laude).<\/p>","country":"","companies":[],"created_at":"2025-06-19T21:50:03.000000Z"},{"id":339,"name":"Tiffany Le","title":"Principal","photo":{"id":1836,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1836\/tiffany-le-nea-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1836\/conversions\/tiffany-le-nea-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1836\/conversions\/tiffany-le-nea-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1836\/conversions\/tiffany-le-nea-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"NEA","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tiffany-le-4ab91b20\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-07-14T06:41:25.000000Z"},{"id":338,"name":"Johannes Fischer","title":"Partner","photo":{"id":1835,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1835\/johannes-fischer-wellington-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1835\/conversions\/johannes-fischer-wellington-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1835\/conversions\/johannes-fischer-wellington-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1835\/conversions\/johannes-fischer-wellington-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Wellington Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/hannes-fischer\/","biography":" Johannes joined Wellington Partners in 2020 as a Senior Associate in the Life Sciences team, he was promoted to Principal in 2022 and Partner in 2023.<\/p>\r\n Prior to joining Wellington Partners, Johannes was a Management Consultant at the Life Sciences practice of L.E.K. Consulting, where he managed and executed numerous projects for leading pharma, medical technology and laboratory supplies companies as well as private equity investors. With his team, Johannes provided M&A support, developed corporate strategies, assessed organizations to enhance their performance and explored product strategies for analogue and digital assets in multiple geographies.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n Johannes holds an MSc in Biochemistry, a PhD in Biotechnology and a Medical Doctorate from Technical University Munich, Germany. As part of his PhD research at King Abdullah University of Science and Technology in Jeddah, Saudi-Arabia, Johannes explored the fundamentals of Artificial Metalloenzymes (ArMs) through means of protein crystallography and spectroscopy and developed a novel scaffold that acts as template for future ArMs research.<\/p>\r\n Johannes is a commercial advisor to a cosmetics start-up in Germany and to a food delivery service company in Saudi-Arabia, which he also co-founded.<\/p>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","country":"de","companies":[],"created_at":"2025-07-14T06:29:20.000000Z"},{"id":219,"name":"Frank Bulens","title":"Partner","photo":{"id":1609,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1609\/frank-bulens-imecxpand-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1609\/conversions\/frank-bulens-imecxpand-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1609\/conversions\/frank-bulens-imecxpand-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1609\/conversions\/frank-bulens-imecxpand-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"imec.xpand","linkedin_profile":"https:\/\/www.linkedin.com\/in\/frankbulens\/","biography":" In January 2018 I joined imec.xpand as a Partner. In the mean time we committed our 1st fund of 117 mio EUR to a portfolio of 15 startups and currently raising imec.xpand Fund II which currently stands at 220 mio EUR (actively investing). Imec.xpand is an early stage and growth VC investor with a game-changing approach to turn hardware driven nanotechnology innovation into successful global companies. The fund is independently managed by a team of entrepreneurs, seasoned venture capitalists and business experts, and is targeting ambitious tech start-ups that meet all the criteria to become a successful, scalable ventures with the potential to change the world, and where imec knowledge, expertise and infrastructure can play a determining role in their success. Imec is the world-leading R&D and innovation hub in nano-electronics and digital technologies based in Leuven, Belgium. For more information about imec.xpand, please visit www.imecxpand.com.<\/p>\r\n From 2009 until 2017 Frank was a Partner at Capricorn Venture Partners where he was involved with investments in the health care field (diagnostics, therapeutics, medical devices and digital health-tech) for the Capricorn Health-tech Fund, the Capricorn ICT Fund and the Quest for Growth Fund. Main responsibility was building and managing the portfolio of the Capricorn Health-tech Fund through deal sourcing and active board memberships.<\/p>\r\n Previously, Frank was a executive investment manager within the life science venture capital team at Gimv (Antwerp, Belgium) and a senior scientific advisor within IWT, a research fund organization in Brussels. Prior to Gimv and IWT Frank worked at the Faculty of Medicine, University of Leuven as a PhD and postdoctoral researcher. Frank is trained as an industrial engineer in chemistry\/biochemistry and obtained a Master Degree as well as a PhD in Medical Sciences at the University of Leuven, Belgium.<\/p>\r\n Throughout his nearly 25 years of making active venture capital investments Frank collected a vast experience in building early stage tech companies towards a successful exit through trade sale\/IPO.<\/p>","country":"","companies":[],"created_at":"2025-06-19T21:58:18.000000Z"},{"id":212,"name":"Armen Vidian","title":"Founder & Managing Partner","photo":{"id":1591,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1591\/armen-vidian-recode-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1591\/conversions\/armen-vidian-recode-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1591\/conversions\/armen-vidian-recode-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1591\/conversions\/armen-vidian-recode-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Recode Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/armenatrecodevc\/","biography":" Armen has nearly 30 years of experience as an engineer, entrepreneur, and investor in technology and healthcare. Armen started his career creating first-in-class products in medical technology. He then co-founded BlueTalon [acquired by MSFT], which initially focused on the interface between data federation and clinical trials. His experience in healthcare and technology has focused his interests on the application of generative AI, robotics, AR\/VR, and brain-computer interfaces in healthcare and the life sciences.<\/p>\r\n After BlueTalon, Armen was an early Partner at DCVC, the first venture capital firm with an AI-centric thesis. At DCVC, he played a leadership role in the investment of the first companies applying AI to healthcare and the life sciences. Some of Armen’s board responsibilities included: Board Chairman at Caption Health<\/a> [acquired by GE HealthCare]; and Board Director at Proprio<\/a>. In addition to these responsibilities, Armen led or co-led investment in AbCellera<\/a> [NASD: ABCL], Recursion<\/a> [NASD: RXRX], and Healthmode<\/a> [NASD:MNMD].<\/p>\r\n Armen holds an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) and an M.S. in Management Science and Engineering from Stanford University. His history with data and healthcare goes back to college, during which he co-authored a paper on the use of autoregressive moving average analysis (ARMA) to characterize baroreflex gain in a 1996 issue of the American Journal of Physiology: Heart and Circulation. Originally from Racine, Wisconsin, Armen’s perspective as a venture capitalist is influenced as a first generation college graduate.<\/p>\r\n<\/div>","country":"","companies":[],"created_at":"2025-06-18T22:52:41.000000Z"},{"id":109,"name":"Karin Leire","title":"Investment Director","photo":{"id":1428,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1428\/Karin-Leire-segulah-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1428\/conversions\/Karin-Leire-segulah-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1428\/conversions\/Karin-Leire-segulah-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1428\/conversions\/Karin-Leire-segulah-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Segulah Medical Acceleration","linkedin_profile":"https:\/\/www.linkedin.com\/in\/karin-leire-569b02\/","biography":" With 20 years of experience of clinical research and evidence-based product development derived primarily in leading roles of TFS (a European CRO company), Karin strengthens the investment team with her clinical, regulatory and market access related knowledge. 2017-2023 Karin was the VP of Research & Innovation at Permobil Group and holds a Master degree of biomedical sciences at the University of Uppsala, Sweden.<\/p>","country":"se","companies":[],"created_at":"2025-04-09T23:38:07.000000Z"},{"id":104,"name":"Luc Starmans","title":"Partner","photo":{"id":1412,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1412\/Luc-Starmans-partlands-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1412\/conversions\/Luc-Starmans-partlands-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1412\/conversions\/Luc-Starmans-partlands-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1412\/conversions\/Luc-Starmans-partlands-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Brightlands Venture Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/luc-starmans\/","biography":" Luc joined Brightlands Venture Partners in 2021 and is partner in the BVP Health team. He has a broad experience in healthcare and life sciences. Prior to joining BVP, Luc was senior manager strategy consulting in the health and life sciences practice of KPMG.<\/p>\r\n Luc holds a MSc and a PhD in Biomedical Engineering from Eindhoven University of Technology and performed his academic research in the field of medical imaging at Philips Research (Eindhoven) and Johns Hopkins School of Medicine (Baltimore, USA).<\/p>","country":"nl","companies":[],"created_at":"2025-04-09T23:33:45.000000Z"},{"id":190,"name":"Daniel Allen","title":"Principal","photo":{"id":1519,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1519\/daniel-allen-unorthodox-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1519\/conversions\/daniel-allen-unorthodox-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1519\/conversions\/daniel-allen-unorthodox-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1519\/conversions\/daniel-allen-unorthodox-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Unorthodox Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/daniel-allen-phd-9b792117b\/","biography":" Role:<\/strong> Daniel steers Unorthodox Ventures’ healthcare presence in Israel. With his extensive network and background in medical science, Daniel identifies companies bold enough to try promising new approaches to healthcare.<\/p>\r\n Helping hand:<\/strong> Beyond his scientific background, Daniel advises our portfolio companies as they progress from clinical stage to regulatory approval to in-market success stories.<\/p>\r\n Background:<\/strong> Daniel holds a Ph.D. in immunology and gene therapy, as well as bachelor’s and master’s degrees in biotechnology.<\/p>","country":"","companies":[],"created_at":"2025-06-03T20:07:30.000000Z"},{"id":81,"name":"David Prim","title":"Principal","photo":{"id":1312,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1312\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(11).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1312\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(11)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1312\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(11)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1312\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(11)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Broadview Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/davidprim9\/","biography":" I am passionate about guiding innovative pharmaceutical, biotech, and medical devices companies through strategic decision-making in support of their long-term objectives. At Broadview Ventures, I am helping pursue the fund's mission of accelerating the development of promising technology for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. I bring experience from a PhD in vascular mechanics and more recently time in life science consulting and strategic transactions. <\/p>","country":"","companies":[],"created_at":"2025-04-09T23:04:26.000000Z"},{"id":300,"name":"Robert Hornby","title":"Investment Director","photo":{"id":1782,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1782\/Robert-Hornby-mercia-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1782\/conversions\/Robert-Hornby-mercia-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1782\/conversions\/Robert-Hornby-mercia-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1782\/conversions\/Robert-Hornby-mercia-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Mercia Asset Management","linkedin_profile":"https:\/\/www.linkedin.com\/in\/roberthornby\/","biography":" Venture capital investor at Mercia Asset Management, focused on making investments of £1m - £10m (with the ability to follow on up to £20m) into life science and technology focused companies in the UK. Raf has a decade of operational experience in the biotech sector and holds an M.Sc. in Biochemistry and Biotechnology and an MBA from Vlerick Business School. Subsequently, he spent more than 5 years at Korys, focusing on life science investments. He was involved with several young innovative companies and served as a strategic advisor for European and US-based investment funds.<\/p>","country":"","companies":[],"created_at":"2025-04-10T05:21:55.000000Z"},{"id":421,"name":"Martin Frost","title":"Chairman of the Board","photo":{"id":1998,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1998\/martin-frost-hypervision-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1998\/conversions\/martin-frost-hypervision-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1998\/conversions\/martin-frost-hypervision-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1998\/conversions\/martin-frost-hypervision-europe-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Hypervision Sugical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/martin-frost-cmr1\/","biography":" Commercially-driven leader and advisor of purpose-driven global technology businesses. Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-08-09T03:24:18.000000Z"},{"id":142,"name":"Ehsan Jabbarzadeh","title":"Partner","photo":{"id":1555,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1555\/Headshot-Creator-for-Website---2025-06-13T184525.484.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1555\/conversions\/Headshot-Creator-for-Website---2025-06-13T184525.484-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1555\/conversions\/Headshot-Creator-for-Website---2025-06-13T184525.484-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1555\/conversions\/Headshot-Creator-for-Website---2025-06-13T184525.484-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"IAG Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ehsanjabbarzadeh\/","biography":" Ehsan is an academic entrepreneur turned investor. A Ph.D. graduate from Drexel University’s Chemical and Biological Engineering, he stumbled into entrepreneurship during his postdoc at the California Institute of Technology. Upon starting his career at the University of South Carolina as a Professor, he led his lab to focus on translational research in biomedical engineering. He concurrently pursued an MBA in Finance and Entrepreneurship at the University of Southern California, Marshall School of Business, to strengthen his business acumen. Ehsan was the Founder and CEO of Obsidio Inc, a venture-backed medical device company dedicated to developing innovative technologies for interventional medicine. Obsidio was launched in 2019 and acquired by Boston Scientific in 2022.<\/p>","country":"us","companies":[],"created_at":"2025-04-25T23:42:31.000000Z"},{"id":92,"name":"Srijoy Mahapatra","title":"Divisonal Vice President","photo":{"id":1512,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1512\/Headshot-Creator-for-Website-(71).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1512\/conversions\/Headshot-Creator-for-Website-(71)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1512\/conversions\/Headshot-Creator-for-Website-(71)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1512\/conversions\/Headshot-Creator-for-Website-(71)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Abbott","linkedin_profile":"https:\/\/www.linkedin.com\/in\/srijoy-mahapatra\/","biography":" My mission is to help people live longer and feel better focused on arrhythmias (Atrial Fibrillation). I'm seeking to amplify that impact by adding artificial intelligence (AI) to my skill set. Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-10T05:09:00.000000Z"},{"id":295,"name":"Mark Slack","title":"Chief Medical Officer","photo":{"id":1773,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1773\/mark-slack-cmr-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1773\/conversions\/mark-slack-cmr-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1773\/conversions\/mark-slack-cmr-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1773\/conversions\/mark-slack-cmr-europe-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"CMR Surgical","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mark-slack-3b8a2139\/","biography":" Mark is a Co-Founder and Chief Medical Officer of CMR Surgical. Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-21T17:38:03.000000Z"},{"id":82,"name":"Bibi Marques","title":"Partner","photo":{"id":1533,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1533\/Headshot-Creator-for-Website-(91).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1533\/conversions\/Headshot-Creator-for-Website-(91)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1533\/conversions\/Headshot-Creator-for-Website-(91)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1533\/conversions\/Headshot-Creator-for-Website-(91)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Buenavista Equity Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/bibisattarmarques\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:05:20.000000Z"},{"id":123,"name":"Joey Mason","title":"Venture Partner","photo":{"id":1683,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1683\/joey-mason-claret-europe-final.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1683\/conversions\/joey-mason-claret-europe-final-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1683\/conversions\/joey-mason-claret-europe-final-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1683\/conversions\/joey-mason-claret-europe-final-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Claret Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/joey-mason\/","biography":" I have spent most of my 25+ year career in the life sciences industry, most recently as a VC investor. I have been an executive and non-executive director on 20 private and public boards in Ireland, the UK, continental Europe and the USA. I have invested in early-stage and scaling companies in all sectors of life sciences and healthcare from medical devices to health IT to biotechnology. Prior multi-sector experience includes: co-founding an internet women's health start-up; as executive director of a biotechnology company; and, as a life sciences investment banker.<\/p>","country":"ie","companies":[],"created_at":"2025-04-10T05:26:19.000000Z"},{"id":125,"name":"Edna Lazar","title":"JJDC, Venture Investor","photo":{"id":1564,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1564\/Headshot-Creator-for-Website---2025-06-17T065206.810.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1564\/conversions\/Headshot-Creator-for-Website---2025-06-17T065206.810-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1564\/conversions\/Headshot-Creator-for-Website---2025-06-17T065206.810-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1564\/conversions\/Headshot-Creator-for-Website---2025-06-17T065206.810-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Johnson & Johnson","linkedin_profile":"https:\/\/www.linkedin.com\/in\/edna-lazar-a5797\/","biography":" Experienced marketing and business development executive in healthcare, with a proven track record of success in both strategy and execution. Highly motivated and results-oriented professional, with a passion for making a difference in patients' lives.<\/p>","country":"il","companies":[],"created_at":"2025-04-10T05:31:33.000000Z"},{"id":201,"name":"Ainhoa Manterola Solans","title":"Managing Director","photo":{"id":1561,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1561\/Headshot-Creator-for-Website---2025-06-17T064845.939.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1561\/conversions\/Headshot-Creator-for-Website---2025-06-17T064845.939-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1561\/conversions\/Headshot-Creator-for-Website---2025-06-17T064845.939-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1561\/conversions\/Headshot-Creator-for-Website---2025-06-17T064845.939-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sofina","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ainhoa-manterola-solans-82455b21\/","biography":" With over 10 years of experience in corporate strategy and PE \/ Growth \/ Venture investing, I am an investment professional at Sofina, a listed investment holding managing €9b+ of assets under management. My mission is to identify, evaluate, and execute equity investments in businesses across Europe, the United States, and Asia. With over a decade of experience working in the medical device and diagnostics industry, I've worked across a range of organizations and geographies to achieve my position as the Vice President of Strategic Development for Diagnostics at Hologic.<\/p>\r\n From starting as a sales representative to becoming a VP, I've progressed in leading organizations across North & South America, EMEA and APAC by learning new skills from a range of colleagues and global experiences over my 17+ year career and by believing that I will never stop learning.<\/p>","country":"es","companies":[],"created_at":"2025-04-09T23:40:00.000000Z"},{"id":121,"name":"Filip Pintelon","title":"Investment Director","photo":{"id":1556,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1556\/Headshot-Creator-for-Website---2025-06-13T184702.222.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1556\/conversions\/Headshot-Creator-for-Website---2025-06-13T184702.222-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1556\/conversions\/Headshot-Creator-for-Website---2025-06-13T184702.222-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1556\/conversions\/Headshot-Creator-for-Website---2025-06-13T184702.222-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Capricorn Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/filippintelon\/","biography":" Inspiring Leader & Bridge Builder, combining innovation successes in Healthcare and Technology Business with a passion for transforming ideas into reality - in early-stage ventures and mature businesses.<\/p>","country":"","companies":[],"created_at":"2025-04-10T05:18:51.000000Z"},{"id":118,"name":"David Carter","title":"Partner","photo":{"id":1563,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1563\/Headshot-Creator-for-Website---2025-06-17T065133.469.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1563\/conversions\/Headshot-Creator-for-Website---2025-06-17T065133.469-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1563\/conversions\/Headshot-Creator-for-Website---2025-06-17T065133.469-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1563\/conversions\/Headshot-Creator-for-Website---2025-06-17T065133.469-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"CRG","linkedin_profile":"https:\/\/www.linkedin.com\/in\/david-carter-39bb511\/","biography":" David Carter is a member of CRG’s Founders Group and serves as Partner and member of CRG’s Investment Committee. Mr. Carter joined CRG in 2003 and has more than 30 years of investment and advisory experience. Mr. Carter leads the due diligence efforts related to CRG’s investments in the medical device, specialty pharma, drug delivery, biopharma and tools & diagnostic sectors. Mr. Carter, in addition to focusing on sourcing, execution and monitoring existing CRG investments is responsible for staffing CRG deal teams. Prior to joining CRG, Mr. Carter was a partner at Palestra Capital, a hedge fund focused on risk arbitrage and special situations. Before joining Palestra, Mr. Carter was a high yield analyst at Furman Selz LLC, where he was responsible for coverage of healthcare-related high yield debt. Previously, Mr. Carter was an investment banking analyst in the Healthcare Group at Chemical Bank and a research assistant in the Mergers & Acquisitions Group of Morgan Stanley. Over the course of his career, Mr. Carter has closed in excess of $5 billion of financing activity.<\/p>\r\n Mr. Carter received a Bachelor of Science in finance from The Pennsylvania State University in 1988. He received a Master of Arts degree in information science and systems in 1994 and an M.B.A. in 1996, both from Columbia University.<\/p>","country":"","companies":[],"created_at":"2025-04-10T04:53:12.000000Z"},{"id":79,"name":"Addie Harris","title":"Executive In Residence","photo":{"id":1532,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1532\/Headshot-Creator-for-Website-(89).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1532\/conversions\/Headshot-Creator-for-Website-(89)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1532\/conversions\/Headshot-Creator-for-Website-(89)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1532\/conversions\/Headshot-Creator-for-Website-(89)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"1955 Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/addie-h-6b74604\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:02:02.000000Z"},{"id":90,"name":"Nick Pachuda","title":"Innovation & New Ventures","photo":{"id":1531,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1531\/Headshot-Creator-for-Website-(88).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1531\/conversions\/Headshot-Creator-for-Website-(88)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1531\/conversions\/Headshot-Creator-for-Website-(88)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1531\/conversions\/Headshot-Creator-for-Website-(88)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Precision Life Science Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nickpachuda\/details\/experience\/","biography":" Dr. Nicholas Pachuda serves as the Chief Operating Officer of Portfolio & Development at Peptilogics and has approximately 28 years of clinical and industry experience in life sciences including orthopedics\/medtech and biotech. These included senior R&D, Clinical, Innovation, BD and Commercial P&L leadership roles. He was involved with several successful startups, midcaps and multinationals, including 10 years at Johnson & Johnson. He has led multiple global organic and inorganic development programs with diverse technologies and teams. Dr. Pachuda was trained as a foot and ankle surgeon and completed an international orthopedic trauma fellowship.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:17:40.000000Z"},{"id":207,"name":"Lior Shahory","title":"General Partner","photo":{"id":1583,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1583\/Headshot-Creator-for-Website---2025-06-17T161957.533.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1583\/conversions\/Headshot-Creator-for-Website---2025-06-17T161957.533-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1583\/conversions\/Headshot-Creator-for-Website---2025-06-17T161957.533-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1583\/conversions\/Headshot-Creator-for-Website---2025-06-17T161957.533-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Peregrine Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lior-shahory-523aa75\/","biography":" Lior Shahory has been with Peregrine since 2005. Working closely with entrepreneurs to build successful companies, he contributes extensive experience in investments, due diligence, strategic planning, project management, and business development.<\/p>\r\n Lior serves as CEO of Peregrine’s Incentive tech incubator. Additionally, he served on the boards of Momentis, Restore, Eximo, Cordio, Valtech, Magneto, Mend.io, Marketyze, Endostream, and Eurekify. Prior to Peregrine, he served as deputy director of Israel’s Chief Scientist’s incubator program.<\/p>\r\n Lior holds a BA in economics and business management from the University of Haifa, and an MBA from Tel-Aviv University.<\/p>","country":"il","companies":[],"created_at":"2025-06-17T20:14:15.000000Z"},{"id":153,"name":"Tyler Wanke","title":"Investor & CEO","photo":{"id":1402,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1402\/Headshot-Creator-for-Website-(32).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1402\/conversions\/Headshot-Creator-for-Website-(32)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1402\/conversions\/Headshot-Creator-for-Website-(32)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1402\/conversions\/Headshot-Creator-for-Website-(32)-large.webp"},"category":"investors_strategics","roles":["I","C"],"company_name":"Wanke Family Office\/MadSci","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tyler-wanke-a116862b\/","biography":" Tyler Wanke, MD, MBA, MEM\/MSDI is a MedTech investor, entrepreneur, and professor. He is also CEO & Co-founder of Madison Scientific (MadSci), a UW-Madison spin-out company developing a Smart Shunt for hydrocephalus. Tyler invests in MedTech venture on behalf of his family office as an angel investor. He previously was co-founder\/CEO of Innoblative, a breast cancer ablation company spun out of Northwestern, and currently serves on the board. He has also served on the board of EDGe Surgical, a revenue-stage Orthopaedic and Spine medical device company. <\/p>\r\n Additionally, Tyler is an adjunct professor at Northwestern University where he teaches NUvention Medical, Northwestern’s BioDesign<\/em> curriculum. <\/p>\r\n He completed an MD from Feinberg School of Medicine, MBA from Kellogg School of Management, a Masters of Engineering Management (MEM) \/ Masters of Science of Design Innovation (MSDI) from McCormick School of Engineering \/ Segal Design Institute, and a BS in Neurobiology from the University of Wisconsin – Madison. <\/p>\r\n He volunteers on a Board of Cures Within Reach (CWR), a non-profit dedicated to funding research of “re-purposed” drugs and devices to cure diseases. <\/p>","country":"","companies":[],"created_at":"2025-05-06T22:17:24.000000Z"},{"id":137,"name":"Christoph Massner","title":"Principal","photo":{"id":1624,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1624\/christoph-massner-earlybird-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1624\/conversions\/christoph-massner-earlybird-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1624\/conversions\/christoph-massner-earlybird-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1624\/conversions\/christoph-massner-earlybird-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Earlybird Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-christoph-massner\/","biography":" As an investor with the Health Fund at Earlybird Venture Capital, my role spans the full investment lifecycle from deal sourcing and due diligence to deal execution and portfolio support. I currently serve as Board Director of Hilo (Aktiia), Ariceum Therapeutics, and Noscendo and as a board observer at Alesi Surgical and Shape Memory Medical.<\/p>\r\n My investment focus lies at the intersection of digital health, medical technologies, diagnostics, biopharma, and R&D platforms, sectors where cutting-edge science meets real-world clinical impact.<\/p>\r\n Prior to joining Earlybird in 2018, I spent over seven years conducting research across leading labs in Germany and Australia, and earned a PhD in Synthetic Biology from the Technical University of Munich.<\/p>\r\n <\/p>","country":"de","companies":[],"created_at":"2025-04-25T02:15:35.000000Z"},{"id":110,"name":"Soyoung Park","title":"General Partner","photo":{"id":1585,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1585\/Headshot-Creator-for-Website---2025-06-17T164502.905.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1585\/conversions\/Headshot-Creator-for-Website---2025-06-17T164502.905-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1585\/conversions\/Headshot-Creator-for-Website---2025-06-17T164502.905-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1585\/conversions\/Headshot-Creator-for-Website---2025-06-17T164502.905-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"1004 Venture Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/soyoung-park-mba\/","biography":" My passion is to help founders achieve their vision and positively impact the world by identifying, evaluating, and accelerating promising startups that can create and execute first-in-class solutions. I leverage my healthcare innovation, financial analysis, and business development expertise to invest in and support entrepreneurs in solving the most pressing challenges. I also mentor aspiring entrepreneurs through various organizations, specializing in managing early-stage startup strategies and executing profit maximization projects. My ultimate goal is to improve human well-being and quality of life through venture capital and mentoring.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:38:52.000000Z"},{"id":195,"name":"Susana Amorim Lopes","title":"Investment Manager","photo":{"id":1584,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1584\/Headshot-Creator-for-Website---2025-06-17T164331.985.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1584\/conversions\/Headshot-Creator-for-Website---2025-06-17T164331.985-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1584\/conversions\/Headshot-Creator-for-Website---2025-06-17T164331.985-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1584\/conversions\/Headshot-Creator-for-Website---2025-06-17T164331.985-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Gilde Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/susanaamorimlopes\/","biography":" Susana Amorim joined Gilde in 2021 and focuses on the Healthtech sector. She is involved in deal sourcing, investment diligence, and portfolio management.<\/p>\r\n Prior to joining Gilde, Susana was a Biodesign Innovation fellow at Stanford University, a program that trains a select group of innovators to identify healthcare needs, invent new technologies, and implement products into patient care. Before this, Susana was also selected to participate in the MIT-Harvard Medical School Healthcare Innovation Bootcamp where she helped create a healthcare venture to improve mental health.<\/p>\r\n Susana began her career in structural heart, working as an Engineer and subsequently Project Manager at Xeltis, a clinical-stage start-up creating novel cardiovascular devices through regenerative medicine. She then worked as a Project Manager at Biotronik where she was responsible for and led the development of a new generation transcatheter aortic valve.<\/p>\r\n Susana has a Bachelor of Science and Master of Science in Biomedical Engineering from the University of Minho\/University of Groningen. She also has a certification in project management (PMP) from the Project Management Institute.<\/p>\r\n She is a Portuguese citizen based in Gilde’s US office.<\/p>","country":"","companies":[],"created_at":"2025-06-09T00:21:19.000000Z"},{"id":209,"name":"Catherine Poulin-Filion","title":"Principal, Venture Capital","photo":{"id":1581,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1581\/catherine-poulin-filion-sectoralasset.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1581\/conversions\/catherine-poulin-filion-sectoralasset-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1581\/conversions\/catherine-poulin-filion-sectoralasset-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1581\/conversions\/catherine-poulin-filion-sectoralasset-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Sectoral Asset Management","linkedin_profile":"https:\/\/www.linkedin.com\/in\/catherinepoulinfilion\/","biography":" Bio coming soon.<\/p>","country":"ca","companies":[],"created_at":"2025-06-17T20:57:56.000000Z"},{"id":217,"name":"Fernando Pacheco","title":"Investment Director","photo":{"id":1606,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1606\/fernando-pacheco-endeavour-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1606\/conversions\/fernando-pacheco-endeavour-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1606\/conversions\/fernando-pacheco-endeavour-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1606\/conversions\/fernando-pacheco-endeavour-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Endeavour Vision","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ffmpacheco\/","biography":" Fernando is an Investment Director at Endeavour Vision focused on medical technology, digital health and diagnostics investments, with a particular focus on orthopaedics, robotics, dental, ophthalmology, ENT and GI. Since joining the firm, he has undertaken multiple sector reviews, led deal screening efforts and participated in and directed a number of due diligence projects. Fernando represents Endeavour Vision as a board member for Miach Orthopaedics and Virtual Incision Corporation, and has previously represented Endeavour Vision as a board observer for SOPHiA GENETICS (NASDAQ:SOPH) prior to the company’s IPO in July 2021. He was on deal teams for investments in Miach Orthopaedics, Virtual Incision Corporation, InBrace, Lumeon, SOPHiA GENETICS and CeQur.<\/p>\r\n Prior to joining Endeavour Vision Fernando was an Engagement Manager at McKinsey & Company. There, he led numerous business strategy and organisational projects including therapeutic-area strategy, merger management, process optimisation, operating model re-design, corporate due-diligence and market access and launch preparation. Fernando worked across multiple geographies, including Switzerland, France, Germany, Belgium, UK, US and Brazil and sectors such as diabetes, specialty pharmaceuticals, infectious disease, wound care, surgical instruments, orthopedics and dental. Before McKinsey, Fernando led the development of several orthopaedic trauma solutions at Stryker Orthopaedics R&D in Switzerland – focusing on upper trauma and extremities.<\/p>\r\n Fernando holds an MEng degree in Biomedical and Mechanical Engineering from Imperial College London and the Swiss Federal Institute of Technology (ETH) Zürich. His Masters’ thesis was in cardiovascular fluid mechanics of stented arteries.<\/p>","country":"ch","companies":[],"created_at":"2025-06-19T21:39:45.000000Z"},{"id":191,"name":"Lewis Kilongo","title":"Principal","photo":{"id":1587,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1587\/Headshot-Creator-for-Website---2025-06-17T165006.973.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1587\/conversions\/Headshot-Creator-for-Website---2025-06-17T165006.973-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1587\/conversions\/Headshot-Creator-for-Website---2025-06-17T165006.973-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1587\/conversions\/Headshot-Creator-for-Website---2025-06-17T165006.973-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Unorthodox Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lewis-kasindi-kilongo-167363184\/","biography":" Role:<\/strong> Lewis leads our medtech investment strategy, making lasting connections with the most prolific industry leaders. He’s an expert on cardiovascular medical devices and is turned to by publications including MedCity News for assessing startups.<\/p>\r\n Helping hand:<\/strong> Multilingual, Lewis assists our large number of foreign medical device companies as they enter the U.S. market, helping them avoid common pitfalls.<\/p>\r\n Background:<\/strong> Corporate finance and financial analysis, with degrees in political science and business administration.<\/p>","country":"","companies":[],"created_at":"2025-06-03T20:26:02.000000Z"},{"id":197,"name":"Henry Zubaida","title":"Investment Manager","photo":{"id":1566,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1566\/Headshot-Creator-for-Website---2025-06-17T065514.803.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1566\/conversions\/Headshot-Creator-for-Website---2025-06-17T065514.803-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1566\/conversions\/Headshot-Creator-for-Website---2025-06-17T065514.803-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1566\/conversions\/Headshot-Creator-for-Website---2025-06-17T065514.803-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Gilde Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/henry-zubaida-bb849848\/","biography":" Henry Zubaida joined Gilde Healthcare in 2018 and focuses on the Healthtech sector. He has been involved in several investments including Big Health, Withings and Volta Medical. He is a board observer at FIRE1, Withings and Volta.<\/p>\r\n Prior to joining Gilde, Henry worked in business development for Biolinq, a US based start-up developing a novel generation of Continuous Glucose Monitoring. Before, Henry worked at Merck KGaA: at the Innovation Center in Germany (on blockchains applications) and at the corporate venture arm, M Ventures, in the Netherlands (deal sourcing and evaluation). Prior to this, he was a management consultant in London for several years.<\/p>\r\n Henry is a British citizen with an academic background in Chemistry and a Master’s degree in Bioscience Enterprise from the University of Cambridge. While at Cambridge Henry received the Cambridge University – Young Entrepreneur of the Year Award.<\/p>","country":"gb","companies":[],"created_at":"2025-06-09T00:34:37.000000Z"},{"id":80,"name":"Omid Akhavan","title":"Managing Director & Founder","photo":{"id":1535,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1535\/Headshot-Creator-for-Website-(93).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1535\/conversions\/Headshot-Creator-for-Website-(93)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1535\/conversions\/Headshot-Creator-for-Website-(93)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1535\/conversions\/Headshot-Creator-for-Website-(93)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Anthro Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/martinomidakhavan\/","biography":" Investing across healthcare companies with a network of funds, family offices and HNWs. Experienced founder CEO with a demonstrated history of working in the medical device industry. Skilled in Management, Start-ups, Financing and Leadership. Strong business development professional with a Master of Business Administration (M.B.A.) from Harvard Business School and B.S.\/M.S. in Mechanical Engineering from Carnegie Mellon University. 2021 Forbes Next 1000.<\/p>","country":"us","companies":[],"created_at":"2025-04-25T02:16:30.000000Z"},{"id":95,"name":"Ramin Mousavi","title":"President & Chief Executive Officer","photo":{"id":1436,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1436\/Headshot-Creator-for-Website-(39).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1436\/conversions\/Headshot-Creator-for-Website-(39)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1436\/conversions\/Headshot-Creator-for-Website-(39)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1436\/conversions\/Headshot-Creator-for-Website-(39)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"CathWorks","linkedin_profile":"https:\/\/www.linkedin.com\/in\/raminmousavi\/","biography":" I am passionate about building high-performing teams that design, develop, and launch breakthrough and transformational innovative products and programs that ultimately help patients and change lives. Tim joined BGF in January 2018, after actively supporting BGF on a number of projects over the previous 18 months. Based in London, his main role is to identify and execute investments with a particular focus on tech-oriented propositions. He also takes a lead role in developing relationships with partners that can help BGF better support key industry sectors. Tim has been active in the venture capital and startup ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments, across a broad range of sectors, stages and geographies. He is part of the BGF Investment Committee.<\/p>","country":"","companies":[],"created_at":"2025-07-02T20:42:47.000000Z"},{"id":205,"name":"Laurent Choppe","title":"Managing Partner","photo":{"id":1586,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1586\/Headshot-Creator-for-Website---2025-06-17T164634.891.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1586\/conversions\/Headshot-Creator-for-Website---2025-06-17T164634.891-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1586\/conversions\/Headshot-Creator-for-Website---2025-06-17T164634.891-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1586\/conversions\/Headshot-Creator-for-Website---2025-06-17T164634.891-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Cukierman & Co. Life Sciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/laurentchoppe\/","biography":" Laurent leads Cukierman & Co. Life Sciences since 2008 and has been involved in more than 100 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture-backed and middle market companies for fund raising, licensing deals and M&A transactions as well as strategic projects for key life sciences industry players.<\/p>\r\n Laurent brings an extensive international life sciences experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, medical devices, biotechnology, nutraceuticals, animal health and direct-to-consumer markets.<\/p>\r\n After a veterinary practice and a new venture experience, he worked 10 years in Schering-Plough (acquired by Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, General Manager in Israel and Vice President, Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE) focused on Alzheimer and amyloidosis).<\/p>\r\n Laurent is a board member of Catalyst Investors Club (CIC), Cell-Lipo (www.cell-lipo.com) and N.E.W.S. Navigation (www.newsnavigation.com). He is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and MBA from INSEAD (Fontainebleau). He is married, father of 3, grandfather of 2 and lives in Lausanne (Switzerland) and Tel Aviv (Israel).<\/p>","country":"","companies":[],"created_at":"2025-06-17T19:53:54.000000Z"},{"id":206,"name":"Elena Lovo","title":"Head of Life Sciences, EMEA, Innovation Economy","photo":{"id":1574,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1574\/elena-lovo-jpmorgan-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1574\/conversions\/elena-lovo-jpmorgan-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1574\/conversions\/elena-lovo-jpmorgan-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1574\/conversions\/elena-lovo-jpmorgan-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"J.P. Morgan","linkedin_profile":"https:\/\/www.linkedin.com\/in\/elenalovo\/","biography":" Bio comig soon.<\/p>","country":"","companies":[],"created_at":"2025-06-17T20:12:15.000000Z"},{"id":124,"name":"Brian Englander","title":"Principal","photo":{"id":1596,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1596\/Headshot-Creator-for-Website---2025-06-18T194213.230.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1596\/conversions\/Headshot-Creator-for-Website---2025-06-18T194213.230-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1596\/conversions\/Headshot-Creator-for-Website---2025-06-18T194213.230-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1596\/conversions\/Headshot-Creator-for-Website---2025-06-18T194213.230-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"CRG","linkedin_profile":"https:\/\/www.linkedin.com\/in\/brian-englander-304a0879\/","biography":" Bio coming soon.<\/p>","country":"us","companies":[],"created_at":"2025-04-10T05:29:04.000000Z"},{"id":175,"name":"Elisa El Nouchi","title":"Senior VC Associate - Life Sciences","photo":{"id":1565,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1565\/Headshot-Creator-for-Website---2025-06-17T065353.801.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1565\/conversions\/Headshot-Creator-for-Website---2025-06-17T065353.801-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1565\/conversions\/Headshot-Creator-for-Website---2025-06-17T065353.801-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1565\/conversions\/Headshot-Creator-for-Website---2025-06-17T065353.801-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Bpifrance","linkedin_profile":"https:\/\/www.linkedin.com\/in\/elisa-el-nouchi-aa292aa6\/","biography":" Since 2013, Bpifrance has become the one stop shop for entrepreneurs with a vastly comprehensive toolbox offered in the field to customers through 50 local branches. Our mission is simple: we believe in serving the future, by being entrepreneur-centric and heavily decentralized.<\/p>","country":"","companies":[],"created_at":"2025-05-29T02:34:20.000000Z"},{"id":196,"name":"Chris Allen","title":"Investor","photo":{"id":1567,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1567\/Headshot-Creator-for-Website---2025-06-17T065608.834.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1567\/conversions\/Headshot-Creator-for-Website---2025-06-17T065608.834-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1567\/conversions\/Headshot-Creator-for-Website---2025-06-17T065608.834-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1567\/conversions\/Headshot-Creator-for-Website---2025-06-17T065608.834-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Gilde Healthcare","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christopher-allen-7212581b8\/","biography":" Medical doctor investing in technologies able to give better care at a lower cost. Previously clinical lead and board member of Central London Healthcare E-hub offering online primary care services to over 250,000 patients.<\/p>","country":"","companies":[],"created_at":"2025-06-09T00:33:04.000000Z"},{"id":99,"name":"Craig Cook","title":"Head of Business Development & Licensing","photo":{"id":1439,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1439\/Headshot-Creator-for-Website-(44).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1439\/conversions\/Headshot-Creator-for-Website-(44)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1439\/conversions\/Headshot-Creator-for-Website-(44)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1439\/conversions\/Headshot-Creator-for-Website-(44)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Wyss Center for Bio and Neuroengineering","linkedin_profile":"https:\/\/www.linkedin.com\/in\/craig-cook-38ab4a\/","biography":" Successful C-level career spanning the pharmaceutical and biotechnology sectors, including having served as CEO of publicly listed companies on Nasdaq New York, London AIM, and Nasdaq Stockholm. Accomplished entrepreneur, including having founded and co-founded several life science ventures in the fields of biotech, medtech, and clinical medicine, and holding C-level and board positions in these successful ventures. Mentor and adviser to early stage ventures through funding rounds, growth phases, and exits. Preventive medicine healthcare professional with a deep scientific appreciation and application of human body physiology, biochemistry, neuroscience and the science of longevity. Broad domain expertise in areas such as oncology, neurodegenerative disease, cell and gene therapy, nano medicine, anti-aging, chronic metabolic and cardiovascular diseases, mental health, anti-doping, and elderly care; as well as the practice of anaesthesiology, sedation and pain management. Qualifications include MD medicine, MBA business administration, MSc translational medicine, BSc pharmacology, and DA anaesthesiology.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:28:11.000000Z"},{"id":94,"name":"Zhou Yu","title":"Director, Computed Tomography","photo":{"id":1432,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1432\/zhou-yu-canon-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1432\/conversions\/zhou-yu-canon-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1432\/conversions\/zhou-yu-canon-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1432\/conversions\/zhou-yu-canon-europe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Canon Medical Research USA, Inc.","linkedin_profile":"https:\/\/www.linkedin.com\/in\/yuzhou05\/","biography":" Bio coming soon.<\/p>","country":"","companies":[],"created_at":"2025-04-25T02:23:08.000000Z"},{"id":176,"name":"Jean-Fran\u00e7ois Morin","title":"Investment Director- Life Sciences","photo":{"id":1471,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1471\/jean-francois-morin-bpifrance-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1471\/conversions\/jean-francois-morin-bpifrance-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1471\/conversions\/jean-francois-morin-bpifrance-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1471\/conversions\/jean-francois-morin-bpifrance-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Bpifrance","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jean-fran%C3%A7ois-morin-aa359b48\/","biography":" With over a decade of experience in investment and finance, I currently serve as Investment Director at Bpifrance. I specialize in life sciences, driving strategic investments in biotech and medtech companies. With a strong background in finance and venture capital, I have successfully managed and structured numerous investment deals. My career began at MAZARS as a Financial Auditor, followed by a role at CDC Enterprises. I hold a Master's degree in Finance from EDHEC Business School.<\/p>","country":"","companies":[],"created_at":"2025-05-29T03:11:36.000000Z"},{"id":188,"name":"Shai Ran Sapir, Ph.D., MBA","title":"Cardiovascular Portfolio Lead,","photo":{"id":1516,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1516\/shairansapir-mayoclinic-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1516\/conversions\/shairansapir-mayoclinic-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1516\/conversions\/shairansapir-mayoclinic-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1516\/conversions\/shairansapir-mayoclinic-europe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Mayo Clinic Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/shairansapir\/","biography":" Shai Ran Sapir, Ph.D., MBA, is the Cardiovascular Portfolio Manager at Mayo Clinic Ventures. Mayo Clinic Ventures serves as both the technology transfer office for Mayo Clinic—handling IP licensing, new company formation, know-how agreements, joint development—and Mayo Clinic’s investment arm. It bridges the gap from ideation to commercialization internally and invests externally in companies collaborating with Mayo Clinic to enhance patient care globally.<\/u><\/u><\/p>\r\n Dr. Ran Sapir plays a crucial role in the commercialization of IP developed under Mayo Clinic's Cardiovascular Medicine Division. His responsibilities include identifying promising intellectual property from Mayo Clinic research, recognizing gaps in the market where Mayo Clinic’s innovations can improve care, negotiating various deal structures, and presenting investment opportunities to the appropriate investment committees within Mayo.<\/u><\/u><\/p>\r\n Since joining Mayo Clinic Ventures in 2022, Dr. Ran Sapir has successfully orchestrated numerous licensing agreements, new company formations, strategic alliances, and conducted due diligence on a wide range of investments within the cardiovascular vertical.<\/u><\/u><\/p>\r\n Dr. Ran Sapir holds a Ph.D. in Molecular Biology from Tel Aviv University and an MBA from the Coller School of Management at Tel Aviv University.<\/p>","country":"","companies":[],"created_at":"2025-06-02T21:06:01.000000Z"},{"id":141,"name":"Kelly Krajnik","title":"Senior Director Business Development","photo":{"id":1425,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1425\/Headshot-Creator-for-Website-(36).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1425\/conversions\/Headshot-Creator-for-Website-(36)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1425\/conversions\/Headshot-Creator-for-Website-(36)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1425\/conversions\/Headshot-Creator-for-Website-(36)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Mayo Clinic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kelly-krajnik-93b6909\/","biography":" Kelly joined Business Development in 2006 and is responsible for facilitating the development and commercialization of Mayo Clinic technologies by working with Mayo Clinic staff, external companies, entrepreneurs, and investors. She is a member of the Mayo Clinic Ventures Executive Committee, leads the technology and business development function, and administers MCV’s seed\/angel fund program and chairs its investment committee.<\/p>\r\n Prior to joining Business Development, Kelly worked as a senior research technologist developing and conducting microarray expression protocols in support of Mayo Clinic research programs and served on a Mayo Clinic Institutional Review Board.<\/p>\r\n Kelly received her BS in Microbiology from University of Wisconsin – La Crosse, and her MBA from the University of St. Thomas. She is also a registered Patent Agent with the USPTO.<\/p>","country":"us","companies":[],"created_at":"2025-04-25T23:34:11.000000Z"},{"id":86,"name":"Kristien Esser","title":"CEO","photo":{"id":1441,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1441\/Headshot-Creator-for-Website-(46).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1441\/conversions\/Headshot-Creator-for-Website-(46)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1441\/conversions\/Headshot-Creator-for-Website-(46)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1441\/conversions\/Headshot-Creator-for-Website-(46)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"GS Capital Connect","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kristienesser2008\/","biography":" For over 27 years, I have been connecting Talent & Capital with Early-Stage MedTech companies. Med Tech executive with over 20 years experience across R&D, product management, sales, marketing and corporate strategy leadership roles<\/p>","country":"","companies":[{"id":16,"name":"Berlin Heals","logo":{"id":1039,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1039\/berlinheals_logo.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1039\/conversions\/berlinheals_logo-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1039\/conversions\/berlinheals_logo-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1039\/conversions\/berlinheals_logo-large.webp"},"type":"presenter","description":" Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T05:04:13.000000Z"}],"created_at":"2025-04-06T05:04:14.000000Z"},{"id":20,"name":"Ruben Molina","title":"CEO & Co-Founder","photo":{"id":1443,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1443\/Headshot-Creator-for-Website-(48).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1443\/conversions\/Headshot-Creator-for-Website-(48)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1443\/conversions\/Headshot-Creator-for-Website-(48)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1443\/conversions\/Headshot-Creator-for-Website-(48)-large.webp"},"category":"innovators","roles":["C"],"company_name":"INNITIUS","linkedin_profile":"https:\/\/www.linkedin.com\/in\/molinaruben\/","biography":" Rubén Molina is a Building Engineer specializing in Structural Calculation and a Structural Engineer specializing in Biomechanics and damage assessment of human tissue with non-destructive techniques, both from the University of Granada. He has also completed the Advanced Management Program at IESE Business School. Rubén is the CEO & Co-founder of INNITIUS and has been recognized as one of the top 100 entrepreneurial profiles in Spain 2023 and Forbes 30 under 30 2023.<\/p>\r\n<\/div>\r\n He has been entrepreneurial since the beginning of his professional career, starting in research. During his PhD, Rubén's curiosity in the technology now being developed by INNITIUS led him to not finish his PhD thesis and create the company. He is a young professional with a lot of energy, driven by challenges, and has a clear vision for the company with discipline and focus.<\/p>\r\n<\/div>\r\n Although he began his career in science, Rubén's core skills now lie in managing and leading the business, understanding obstetricians' needs, and translating them into the company's vision. Over 8 years, INNITIUS has achieved significant milestones such as progressing from a laboratory prototype to a frozen, clinically validated product design, assembling a team of over 15 people, and securing over €7M of funding to advance the product's development. Their aim is to eliminate the uncertainty associated with birth timing, impacting the lives of million of women worldwide each year.<\/p>\r\n<\/div>","country":"","companies":[{"id":20,"name":"INNITIUS","logo":{"id":1048,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1048\/Innitius_400x400.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1048\/conversions\/Innitius_400x400-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1048\/conversions\/Innitius_400x400-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1048\/conversions\/Innitius_400x400-large.webp"},"type":"presenter","description":" INNITIUS develops a medical device that combines intravaginal hardware to measure cervical tissue consistency with shear elastic waves and machine learning algorithms. The device aims to provide diagnostics for multiple women’s health conditions related to childbirth timing, with dedicated algorithms for each specific indication<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T05:19:30.000000Z"}],"created_at":"2025-04-06T05:19:31.000000Z"},{"id":9,"name":"Jochen Rein\u00f6hl","title":"CEO","photo":{"id":1329,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1329\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(28).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1329\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(28)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1329\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(28)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1329\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(28)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Coramaze Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jochen-o-reinoehl-md\/","biography":" Dr. med. habil. Jochen Reinöhl, CEO of Coramaze Technologies, combines extensive experience as a business leader, interventional cardiologist, researcher, and health economic expert. With a proven track record in high-impact roles within hospitals and leading medtech companies, Dr. Reinöhl excels in building high-performing teams, driving operational excellence, and accelerating product life cycles. Coramaze Technologies is developing an fast end effective solution for the treatment of tricuspid regurgitation. The TriPair system is deigned to be anchored atraumatically to the right atrium. The device is intended to be easily placed in a procedure taking less than twenty minutes, without the need for anesthesia or TEE. TriPair is agnostic of valve morphology and can be retrieved if necessary<\/p>\r\n Visit website<\/a>.<\/p>","created_at":"2025-04-05T18:01:53.000000Z"}],"created_at":"2025-04-05T18:01:54.000000Z"},{"id":7,"name":"Jacob Ahrnstein","title":"CEO & Co-founder","photo":{"id":1324,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1324\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(23).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1324\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(23)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1324\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(23)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1324\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(23)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Njord Medtech","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jacob-ahrnstein-a5310038\/","biography":" Jacob is the co-founder of Njord Medtech and holds the position as CEO since mid-2022. Early tenure involves radiology, fintech, and digital mobility ventures as well as supporting executive management on their next investment decision. <\/p>","country":"","companies":[{"id":7,"name":"Njord Medtech","logo":{"id":1020,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1020\/njord.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1020\/conversions\/njord-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1020\/conversions\/njord-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1020\/conversions\/njord-large.webp"},"type":"presenter","description":" Njord is a medtech spin-off from Sahlgrenska University Hospital with a mission to solve unmet needs in radiology and patient handling. The first product launched is a novel patient transfer device (co-bot solution) Atle® 180 enabling improved efficiency and quality of care for acute care departments. The solution is already in use by +30 hospitals in Northern Europe.<\/p>\r\n Visit website<\/em><\/a>. <\/p>","created_at":"2025-04-05T17:42:21.000000Z"}],"created_at":"2025-04-05T17:45:24.000000Z"},{"id":11,"name":"Jeff Luber","title":"CEO","photo":{"id":1440,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1440\/Headshot-Creator-for-Website-(45).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1440\/conversions\/Headshot-Creator-for-Website-(45)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1440\/conversions\/Headshot-Creator-for-Website-(45)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1440\/conversions\/Headshot-Creator-for-Website-(45)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Clairity","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeffrey-r-luber-2003154\/","biography":" Jeff Luber is the CEO of Clairity. As a veteran life sciences and award-winning CEO, Jeff has served as CEO of multiple healthcare companies across oncology, genetic sequencing, infectious disease and digital health. Prior to joining Clairity, Jeff served as CEO of binx health where he led the company from proof-of-concept through FDA clearance and rapid commercialization of the first ever point-of-care molecular platform of its kind for infectious disease testing and he continues to serve as the company’s Chairman. Prior to binx, Jeff served as CEO of Good Start Genetics, the first company to bring next generation sequencing to reproductive health. Under Jeff’s leadership, testing volumes grew by double digits, revenues climbed to the highest mark in the company’s history, culminating in the successful sale of the company in August 2017.<\/p>\r\n Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University. He is also the winner of the 2022 EY Entrepreneur of the Year Award and currently serves as a judge for the annual competition. <\/p>\r\n<\/div>","country":"","companies":[{"id":11,"name":"Clairity","logo":{"id":1029,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1029\/Screenshot-2024-11-22-134100.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1029\/conversions\/Screenshot-2024-11-22-134100-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1029\/conversions\/Screenshot-2024-11-22-134100-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1029\/conversions\/Screenshot-2024-11-22-134100-large.webp"},"type":"presenter","description":" Clairity develops AI-driven tools to enhance breast cancer screening and risk assessment.<\/span> Its platform utilizes deep learning models to analyze mammographic images, aiming to improve early detection, reduce racial and ethnic biases, and personalize care plans.<\/span> The technology is grounded in decades of research led by Dr. Connie Lehman at institutions such as Mass General Brigham and MIT.<\/span> Clairity's approach seeks to transform mammography from a one-size-fits-all model to a precision medicine framework.<\/span><\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T04:33:17.000000Z"}],"created_at":"2025-04-06T04:33:18.000000Z"},{"id":24,"name":"Lara Zibners","title":"Co-Founder & Chairman","photo":{"id":1413,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1413\/Lara-Zibners-calla-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1413\/conversions\/Lara-Zibners-calla-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1413\/conversions\/Lara-Zibners-calla-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1413\/conversions\/Lara-Zibners-calla-europe-large.webp"},"category":"innovators","roles":["C"],"company_name":"Calla Lily Clinical Care","linkedin_profile":"https:\/\/www.linkedin.com\/in\/laraz\/","biography":" Bio coming soon.<\/p>","country":"","companies":[{"id":23,"name":"Calla Lily Clinical Care","logo":{"id":1054,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1054\/calla_lily_clinical_care_logo.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1054\/conversions\/calla_lily_clinical_care_logo-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1054\/conversions\/calla_lily_clinical_care_logo-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1054\/conversions\/calla_lily_clinical_care_logo-large.webp"},"type":"presenter","description":" Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T05:28:07.000000Z"}],"created_at":"2025-04-06T05:28:09.000000Z"},{"id":132,"name":"Tim Keane","title":"Co-Founder & CEO","photo":{"id":1327,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1327\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(26).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1327\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(26)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1327\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(26)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1327\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(26)-large.webp"},"category":"innovators","roles":["C"],"company_name":"TYBR Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/timjkeanejr\/","biography":" Bio coming soon.<\/p>","country":"","companies":[{"id":80,"name":"TYBR Health","logo":{"id":1282,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1282\/Screenshot-2024-12-20-230122.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1282\/conversions\/Screenshot-2024-12-20-230122-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1282\/conversions\/Screenshot-2024-12-20-230122-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1282\/conversions\/Screenshot-2024-12-20-230122-large.webp"},"type":"presenter","description":" TYBR Health is developing a natural hydrogel to prevent adhesions (internal scarring) that can occur following minimally invasive surgery. The technology is intended to reduce post-operative complications which can cause patients pain and require rehabilitation following tendon and joint surgeries. <\/p>\r\n Visit website<\/a>.<\/em><\/p>","created_at":"2025-04-19T21:37:00.000000Z"}],"created_at":"2025-04-19T21:37:01.000000Z"},{"id":12,"name":"Berk Tas","title":"CEO","photo":{"id":1331,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1331\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(30).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1331\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(30)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1331\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(30)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1331\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(30)-large.webp"},"category":"innovators","roles":["C"],"company_name":"SentiAR","linkedin_profile":"https:\/\/www.linkedin.com\/in\/berk-tas-ab537722\/","biography":" Mr. Tas will share the story of SentiAR at the Emerging Medtech Summit and will provide updates on strategic partnering and investment opportunities.<\/p>\r\n Berk serves as the Chief Executive Officer and President of SentiAR. Berk has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. Prior to joining SentiAR he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, he played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. Prior to that he served in various leadership roles at Sunshine Heart developing a first of its kind, heart failure therapy and at Boston Scientific developing several novel therapies and technologies focused in Cardiac Rhythm Management. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University.<\/p>","country":"","companies":[{"id":12,"name":"SentiAR","logo":{"id":1031,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1031\/sentiAR.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1031\/conversions\/sentiAR-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1031\/conversions\/sentiAR-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1031\/conversions\/sentiAR-large.webp"},"type":"presenter","description":" Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T04:47:09.000000Z"}],"created_at":"2025-04-06T04:47:09.000000Z"},{"id":10,"name":"Tim Tobin","title":"CEO","photo":{"id":1323,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1323\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(22).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1323\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(22)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1323\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(22)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1323\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(22)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Planatome","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tim-tobin-3aa3023\/","biography":" Tim Tobin is co-founder and CEO of Planatome, LLC. Planatome® is a patented technology platform, adapted from semiconductor manufacturing and licensed to industry leaders to create the world’s most advanced surgical cutting instruments. This technology yields tremendous healing benefits for patients and economic benefits for healthcare companies.<\/p>\r\n Prior to Planatome, Tim was co-founder and CEO of Entrepix, Inc., a semiconductor company who specializes in chemical mechanical polishing (CMP) of chips that power everything from AI and EVs, to 5G and mobile devices. Acquired by Amtech Systems, Inc. (NASDAQ: ASYS) in 2023, Entrepix spent 25 years developing the largest portfolio of CMP processes in the world. Recognizing the opportunity to harness the power of CMP for industries outside chip manufacturing, Planatome was founded in 2017, initially focused on the medical device market.<\/p>\r\n Tim holds a Master in Microelectronic Manufacturing from RIT and a Bachelor in Applied Physics from the State University of New York at Geneseo.<\/p>","country":"us","companies":[{"id":10,"name":"Planatome","logo":{"id":1027,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1027\/Planatome_Logo_CMYK_Blue.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1027\/conversions\/Planatome_Logo_CMYK_Blue-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1027\/conversions\/Planatome_Logo_CMYK_Blue-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1027\/conversions\/Planatome_Logo_CMYK_Blue-large.webp"},"type":"presenter","description":" Planatome is a patented technology platform<\/em>, adapted from semiconductor manufacturing and licensed to industry leaders to create the world’s most advanced surgical cutting instruments – think semiconductor meets medical.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T04:26:11.000000Z"}],"created_at":"2025-04-06T04:30:13.000000Z"},{"id":2,"name":"James Mainwaring","title":"Chief Commercial & Operating Officer","photo":{"id":1326,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1326\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(25).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1326\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(25)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1326\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(25)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1326\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(25)-large.webp"},"category":"innovators","roles":["C"],"company_name":"Innotive Diagnostics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jftmainwaring\/","biography":" James has experience in setting up key operating functions in early stage companies and delivering strategic analysis projects. Before moving into the medical device industry, James was a medical device investment analyst covering the US and European medical device markets at Atlantic Equities and before that at US investment bank, Stifel. James has a degree in Biology from the University of Bristol and is a CFA Charterholder.<\/p>","country":"","companies":[{"id":2,"name":"Innotive Diagnostics","logo":{"id":1008,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1008\/Innotive_DX_RGB_Primary_Dark.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1008\/conversions\/Innotive_DX_RGB_Primary_Dark-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1008\/conversions\/Innotive_DX_RGB_Primary_Dark-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1008\/conversions\/Innotive_DX_RGB_Primary_Dark-large.webp"},"type":"presenter","description":" Innotive Diagnostics is developing a novel bacterial infection diagnostic system to revolutionise the diagnosis of urinary tract infections (UTIs). Delivering a 99% reduction in time to result at the point of care using its diagnostic system vs. gold standard laboratory methods. Innotive’s technology is based on novel single-cell analysis that could be applicable across a range of bacterial infections.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-05T17:01:19.000000Z"}],"created_at":"2025-04-05T17:01:20.000000Z"},{"id":6,"name":"Francis White","title":"CEO","photo":{"id":1433,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1433\/Francis-White-heartbiotech-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1433\/conversions\/Francis-White-heartbiotech-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1433\/conversions\/Francis-White-heartbiotech-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1433\/conversions\/Francis-White-heartbiotech-europe-large.webp"},"category":"innovators","roles":["C"],"company_name":"Heart Biotech","linkedin_profile":"https:\/\/www.linkedin.com\/in\/franciswhite\/","biography":" Francis White, MBA, is a transformative business leader with expertise in strategic planning, operational excellence, and financial stewardship. Business Director at Medtronic Ltd, MD of Olympus Ltd and COO of Adherium, driving innovation, increasing profitability, and cultural change. Passionate about how technology can positively change and impact patient outcomes.<\/p>","country":"","companies":[{"id":6,"name":"Heart Biotech","logo":{"id":1018,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1018\/heart_biotech.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1018\/conversions\/heart_biotech-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1018\/conversions\/heart_biotech-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1018\/conversions\/heart_biotech-large.webp"},"type":"presenter","description":" The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body’s own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-05T17:31:47.000000Z"}],"created_at":"2025-04-05T17:34:25.000000Z"},{"id":131,"name":"George Kramer","title":"Founder & CEO","photo":{"id":1280,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1280\/Kramer_George_-neocor.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1280\/conversions\/Kramer_George_-neocor-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1280\/conversions\/Kramer_George_-neocor-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1280\/conversions\/Kramer_George_-neocor-large.webp"},"category":"innovators","roles":["C"],"company_name":"NeoCor","linkedin_profile":"https:\/\/www.linkedin.com\/in\/george-kramer-2a64b034\/","biography":" NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach.<\/span> The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery.<\/span> The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure.<\/span> CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.<\/span>\u200b<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-19T21:33:30.000000Z"}],"created_at":"2025-04-19T21:30:00.000000Z"},{"id":3,"name":"Oriol Iborra","title":"CEO & Co-Founder","photo":{"id":1333,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1333\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(32).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1333\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(32)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1333\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(32)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1333\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(32)-large.webp"},"category":"innovators","roles":["C"],"company_name":"NIMBLE","linkedin_profile":"https:\/\/www.linkedin.com\/in\/oriol-iborra-egea-phd-52144593\/","biography":" Biologist, BSc (molecular, cellular and systems biology), Geneticist, MSc (Human genetics and genomics) and PhD (cardiovascular research). Entrepreneur and Scientific Researcher<\/p>\r\n Creative and business-savvy R&D professional with 10 years of progressive experience across a broad range of basic to translational activities within the public healthcare industry. I'm a young, passionate scientist with a leading track record in and out of the laboratory, working with cutting edge technologies to solve real patient needs. A strong vision and ingenuity have led me to patent and develop two different assets that are moving rapidly towards clinical use, and to establish several national and international collaborations to publish in the best journals of the world. Personally, I strive to make scientific research available to the general public by taking leading positions in the most important scientific societies, and uphold equality and diversity values across STEM disciplines.<\/p>\r\n I have co-founded NIMBLE diagnostics (and exercise as CEO) with the goal of empowering one of our most impactful research projects with the resources necessary to get to the clinical scenario and help millions of patients and clinicians who are currently left without any tools to understand the integrity of stents once implanted.<\/p>","country":"","companies":[{"id":3,"name":"NIMBLE","logo":{"id":1010,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1010\/nimble_diagnostics_logo.jpeg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1010\/conversions\/nimble_diagnostics_logo-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1010\/conversions\/nimble_diagnostics_logo-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1010\/conversions\/nimble_diagnostics_logo-large.webp"},"type":"presenter","description":" NIMBLE is developing a first-in-class, non-invasive, non-ionizing system to monitor coronary stent health using microwave-based technology. Designed to detect occlusion, fracture, or migration, the NIMBLE System provides cardiologists with objective data on stent status—without relying on invasive angiograms. With over 4 million stents implanted annually and a 30% failure rate within two years, NIMBLE addresses an $8B market with the goal of improving outcomes and saving lives.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-05T17:11:05.000000Z"}],"created_at":"2025-04-05T17:11:05.000000Z"},{"id":18,"name":"Diku Mandavia","title":"Chief Medical Officer","photo":{"id":1845,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1845\/Diku-Mandavia-deepsight-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1845\/conversions\/Diku-Mandavia-deepsight-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1845\/conversions\/Diku-Mandavia-deepsight-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1845\/conversions\/Diku-Mandavia-deepsight-europe-large.webp"},"category":"innovators","roles":["C"],"company_name":"Deepsight Technology","linkedin_profile":"https:\/\/www.linkedin.com\/in\/diku-mandavia\/","biography":" Health technology innovation & medical device commercialization: I am a pioneer in point of care ultrasound and a recognized global expert in point of care diagnostics, neurodiagnostics, imaging, robotics and artificial intelligence (AI). Broad knowledge of global healthcare delivery, current trends, and implications for healthcare companies & organizations. Expert in medical device commercialization of disruptive technology. (serial CMO) Extensive experience managing global teams, medical affairs and budgets. Recognized clinical educator, expert, and researcher with >100 publications and 230 invited lectures. DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T05:13:37.000000Z"}],"created_at":"2025-04-06T05:13:38.000000Z"},{"id":22,"name":"Caitlin Morse","title":"CEO","photo":{"id":1411,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1411\/Caitlin-Morse-brainspace-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1411\/conversions\/Caitlin-Morse-brainspace-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1411\/conversions\/Caitlin-Morse-brainspace-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1411\/conversions\/Caitlin-Morse-brainspace-europe-large.webp"},"category":"innovators","roles":["C"],"company_name":"BrainSpace","linkedin_profile":"https:\/\/www.linkedin.com\/in\/caitlinmorse\/","biography":" Caitlin Morse is the CEO & Co-founder of BrainSpace, an early stage start-up that has developed the patented, FDA-pending Intellidrop, automated acute brain pressure management for Stroke, TBI, neurosurgery and neurodegeneration (NPH-induced dementia). Beyond this first device, BrainSpace is leveraging proprietary CSF access to build a Techmed Neuro platform powered by device-generated data streams and continuous biomarkers. Prior to BrainSpace, Caitlin worked in medical device development with Flex, one of the world’s largest contract manufacturers, and running a product development consulting for venture-backed medtech start-ups. Reach out for discussions on data, automation, novel sensors, and all things neuro.<\/span><\/p>","country":"","companies":[{"id":22,"name":"BrainSpace","logo":{"id":1052,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1052\/braiinspace.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1052\/conversions\/braiinspace-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1052\/conversions\/braiinspace-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1052\/conversions\/braiinspace-large.webp"},"type":"presenter","description":" BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians.<\/p>\r\n Visit website<\/em><\/a>.<\/p>","created_at":"2025-04-06T05:26:28.000000Z"}],"created_at":"2025-04-06T05:26:30.000000Z"},{"id":26,"name":"Raman Kapoor","title":"Chief Healthspan Officer and BioGut","photo":{"id":1716,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1716\/raman-kapoor-bioaro.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1716\/conversions\/raman-kapoor-bioaro-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1716\/conversions\/raman-kapoor-bioaro-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1716\/conversions\/raman-kapoor-bioaro-large.webp"},"category":"innovators","roles":["C"],"company_name":"The BioSport","linkedin_profile":"https:\/\/www.linkedin.com\/in\/raman-kapoor-b227a211\/","biography":" As a mother, a registered dietitian, and a philanthropist, Raman has used her professional expertise and experience, to make a difference. During the course of her life and career she has gained a deeper insight to the power of prevention, and how education, knowledge transfer, and building capacity in those around her can lead to empowerment, and the confidence to make a positive change. Raman believes that one size does not fit all, and that prevention and management should be customized to each person, based on their individual lifestyle, genetics and microbiome. This passion fueled her vision of the NEA Medical Aesthetic Clinic, and teaching people how to try to achieve their best health through BioAro Inc. BioAro is a biotechnology company helping Canadians bring precision medicine into everyday life, allowing people to be the “CEO of their own health.” Raman has also co-founded a charity focusing on wellness, touching the lives of over 25,000 people. With more than 20 years of volunteering, and working experience, she seeks out local solutions that help people live healthier lives. Raman believes in practicing what she preaches, in all facets of her life, and loves to speak publicly. Raman was the successful recipient of the Women of Inspiration Award in the category of Difference Maker.<\/p>","country":"","companies":[{"id":25,"name":"The BioSport","logo":{"id":2064,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/2064\/The-BioSport-Official-Logo_0808.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/2064\/conversions\/The-BioSport-Official-Logo_0808-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/2064\/conversions\/The-BioSport-Official-Logo_0808-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/2064\/conversions\/The-BioSport-Official-Logo_0808-large.webp"},"type":"presenter","description":" The BioSport™<\/strong> is an AI-powered, multi-omics platform that merges genetics, biomarkers, and wearable data to optimize athletic performance and safety. Its unique BioFit™ Score<\/strong>, analyzing 15,000+ sport-related variants, delivers hyper-personalized training, nutrition, and recovery plans. Athletes and coaches gain data-driven real-time insights via The BioSport interactive App to enhance results, reduce injury risk, and unlock peak potential.<\/p>\r\n
Barten studied medical technology at the University of Applied Sciences in Ulm, Germany, from 1988 to 1993, and holds a degree in business administration.<\/span><\/p>","country":"","companies":[],"created_at":"2025-04-29T16:15:26.000000Z"},{"id":189,"name":"Carey Smith","title":"Founding Contrarian","photo":{"id":1518,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1518\/Headshot-Creator-for-Website-(74).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1518\/conversions\/Headshot-Creator-for-Website-(74)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1518\/conversions\/Headshot-Creator-for-Website-(74)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1518\/conversions\/Headshot-Creator-for-Website-(74)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Unorthodox Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jcareysmith\/","biography":"\r\n
\r\n
\uf0a7 Expert in analytics applied to commercial and clinical operations in biopharma and health systems
\uf0a7 Unique breadth of experience across the healthcare eco-system: payor, provider, supply chain, biopharma and health IT companies. Deep understanding of stakeholder dynamics and value creation opportunities<\/span><\/p>","country":"","companies":[],"created_at":"2025-04-09T23:25:09.000000Z"},{"id":89,"name":"Christopher Shen","title":"Partner","photo":{"id":1505,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1505\/Headshot-Creator-for-Website-(64).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1505\/conversions\/Headshot-Creator-for-Website-(64)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1505\/conversions\/Headshot-Creator-for-Website-(64)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1505\/conversions\/Headshot-Creator-for-Website-(64)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Novo Holdings","linkedin_profile":"https:\/\/www.linkedin.com\/in\/christopher-shen-md\/","biography":"
Interested in healthcare ventures and new technologies
Helping entrepreneurs to establish a business and develop a business model
Coach entrepreneurs in their endeavors
Investing in new healthcare startups
Creating a superior return for investors by helping humankind
Specialties: marketing, sales, product development, medical devices, incubators, coaching, financing, venture capital.<\/p>","country":"de","companies":[],"created_at":"2025-04-25T02:20:21.000000Z"},{"id":334,"name":"Josep Ll. Sanfeliu","title":"Co-founder and managing partner","photo":{"id":1888,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1888\/Headshot-Creator-for-Website---2025-07-22T075718.671.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1888\/conversions\/Headshot-Creator-for-Website---2025-07-22T075718.671-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1888\/conversions\/Headshot-Creator-for-Website---2025-07-22T075718.671-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1888\/conversions\/Headshot-Creator-for-Website---2025-07-22T075718.671-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Asabys Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jsanfeliuinvestinlife\/","biography":"
Specialities: Over 18 years of intensive experiences across Europe, North America & Asia. Leading teams, identifying and developing talent. Experience in implant, capital and disposable businesses with expereince in helping develop smaller ($50million) and larger ($1B) businesses.<\/p>","country":"","companies":[],"created_at":"2025-07-19T23:09:53.000000Z"},{"id":88,"name":"John White","title":"Managing Director","photo":{"id":1508,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1508\/Headshot-Creator-for-Website-(67).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1508\/conversions\/Headshot-Creator-for-Website-(67)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1508\/conversions\/Headshot-Creator-for-Website-(67)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1508\/conversions\/Headshot-Creator-for-Website-(67)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"KCK Group","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnwarrenwhite\/","biography":"
Driving Digital transformation in healthcare and Build an engineering\/business organization to deliver from conception to market ready solutions.
Solutions Portfolio Management from pathfinding to launch to sustaining.
Ideation, Conception, Design and Development hardware and software technology platforms for complexe\/Deep tech medical devices.
Experience with international Medical Device regulations and IP Strategy.
Business Development, Licensing and M&A experience.
First author of several patents and publications in the field of Computer Assisted Surgery, artificial intelligence, robotics and IoMT.<\/p>","country":"","companies":[],"created_at":"2025-04-10T05:43:56.000000Z"},{"id":174,"name":"Dr. John Yianni","title":"Partner","photo":{"id":1857,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1857\/John-Yianni-earlybird-europe-final.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1857\/conversions\/John-Yianni-earlybird-europe-final-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1857\/conversions\/John-Yianni-earlybird-europe-final-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1857\/conversions\/John-Yianni-earlybird-europe-final-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Earlybird Health","linkedin_profile":"https:\/\/www.linkedin.com\/in\/john-yianni-8132a2\/","biography":"
Specialties: Cardiovascular Bioengineering, Patient-specific modeling of blood flow and wall motion, magnetic resonance imaging techniques to measure blood flow during dynamic exercise conditions, tracking the motion of blood vessels over the cardiac cycle, and determining realistic loading conditions for modeling implanted devices.<\/span><\/p>","country":"us","companies":[],"created_at":"2025-08-22T19:02:19.000000Z"},{"id":105,"name":"Alexander Schmitz","title":"Partner","photo":{"id":1303,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1303\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(1).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1303\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(1)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1303\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(1)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1303\/conversions\/Agilis-Robotics-\u2013-based-in-HK-Cornerstone-Robotics-\u2013-based-in-China-Ronovo-Robotics-\u2013-based-in-China-Eric-Loh-\u2013-Trendlines-Singapore-Zhou-Fangzhou-\u2013-Nice-Surgical-based-in-Singapore-Colin-Tan-\u2013-Co-(1)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Endeavour Vision","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alexander-schmitz-41194\/","biography":"\r\n
responsible for its Image Guided Therapy (IGT) investments. He currently serves on over a half dozen
of the portfolio’s boards; previous director positions include Corindus Vascular Robotics (CVRS) and
Affera. He also oversees its ‘fund-of-funds’ investing.
Prior to moving to Philips Ventures in 2021, Nate was the Head of Business Development for the IGT
cluster following the acquisition of Volcano. He oversaw acquisitions of Spectranetics, Cardioprolific,
EPD, Vesper Medical and led investments in various start-ups currently in the IGT portfolio.
Prior to Philips, Nate worked 9 years at Boston Scientific Corporation (BSX) where he held various
roles in both product management for Peripheral Interventions division and business development
for the Cardiac Rhythm & Vascular group. Before BSC Nate spent 6 years in management consulting,
including 3 years at Heath Advances focused on evaluating the commercial potential of emerging
medical technology ranging from biotech and diagnostics to medical devices.
Nate received his MBA from the Yale School of Management and his BA from Brown University.<\/p>","country":"us","companies":[],"created_at":"2025-05-23T19:04:52.000000Z"},{"id":117,"name":"Gautam Kainth","title":"Partner","photo":{"id":1514,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1514\/Headshot-Creator-for-Website-(73).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1514\/conversions\/Headshot-Creator-for-Website-(73)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1514\/conversions\/Headshot-Creator-for-Website-(73)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1514\/conversions\/Headshot-Creator-for-Website-(73)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"TCP Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gautamkainth\/","biography":"
My expertise spans venture capital, investment strategy, deal structuring, and portfolio management—guiding startups and growth-stage companies toward success. I actively contribute to value creation through Investment Committees, Board Directorships, and Advisory Roles, ensuring strategic alignment and impact-driven growth.
I am particularly passionate about Medtech and Healthtech innovations, supporting groundbreaking companies in cardiovascular, ophthalmology, remote patient monitoring, mental health, oncology and surgical devices. I focus on Series A, B, and C rounds, investing between $5M-$15M per deal, with a track record of identifying category-defining technologies.<\/p>","country":"gb","companies":[],"created_at":"2025-04-10T04:46:57.000000Z"},{"id":210,"name":"Mukul Mohanty","title":"Senior Partner","photo":{"id":1600,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1600\/Headshot-Creator-for-Website---2025-06-18T231303.103.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1600\/conversions\/Headshot-Creator-for-Website---2025-06-18T231303.103-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1600\/conversions\/Headshot-Creator-for-Website---2025-06-18T231303.103-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1600\/conversions\/Headshot-Creator-for-Website---2025-06-18T231303.103-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Truffle Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mukul-mohanty-61898a5a\/","biography":"
Mukul has 26 years of investment experience, 13 fundraising experience and 14 years of transaction and deal experience in Europe, Asia and the US.
Mukul has developed, led and executed fundraising strategies for multiple campaigns from closed end funds to individual mandates. He has built an excellent roster of PEs, VCs, CVCs, Funds of Funds, Tier-1 Placement Agents, family offices, and co- investors.
Mukul is a specialist fundraiser, raised and exited multiple closed end funds, and Series A and Series B for specialist mandates.
Mukul also provides pro bono mentoring to early stage start-ups and their founders.<\/p>","country":"","companies":[],"created_at":"2025-06-18T22:00:24.000000Z"},{"id":474,"name":"Bjorn von Siemens","title":"Founder, President","photo":{"id":2112,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/2112\/bjoern-vonsiemens-caresyntax-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/2112\/conversions\/bjoern-vonsiemens-caresyntax-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/2112\/conversions\/bjoern-vonsiemens-caresyntax-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/2112\/conversions\/bjoern-vonsiemens-caresyntax-europe-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Caresyntax","linkedin_profile":"https:\/\/www.linkedin.com\/in\/bjoernvonsiemens\/","biography":"
Today, patients and healthcare professionals are lacking true platform solutions, which are critical to improve and scale access, efficiency and quality of care.
AI and automation have been successfully deployed in many sectors and have the potential to transform and improve healthcare systems. Adoption is in its infancy, hurdles and challenges to bring technological innovations into mainstream use are immense.
As the Founder of Caresyntax, I am committed to improving access, quality and efficiency of surgery. Our talented teams are developing a vendor neutral precision surgery platform. In 2023, Caresyntax enables safer and smarter surgeries for thousands of caregivers and millions of patients every year.
Over the last decade, I also have had the privilege to invest in, partner and mentor some of the most talented entrepreneurs in numerous healthcare sectors in Europe, US, Middle East and beyond.
I am looking forward to making a positive impact in the healthcare ecosystem and beyond; creating the foundation for a more sustainable and peaceful society. Together with our teams, partners, customers, investors and friends; we are committed to helping people live long and fulfilling lives.<\/p>","country":"","companies":[],"created_at":"2025-08-19T19:16:48.000000Z"},{"id":211,"name":"Hubert Birner","title":"Managing Partner","photo":{"id":1598,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1598\/Headshot-Creator-for-Website---2025-06-18T230950.167.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1598\/conversions\/Headshot-Creator-for-Website---2025-06-18T230950.167-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1598\/conversions\/Headshot-Creator-for-Website---2025-06-18T230950.167-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1598\/conversions\/Headshot-Creator-for-Website---2025-06-18T230950.167-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"TVM Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-hubert-birner-563b8b3\/","biography":"
In collaboration with Eli Lilly & Company, I successfully introduced an innovative “asset-centric” financing model for early-stage biopharmaceutical product candidates, reshaping investment strategies in the sector.
Currently, I serve on the boards of several life science companies within the TVM portfolio. Over the years, I have held key leadership roles, including Chairman and Vice Chairman of the Board at Direvo Biotech AG and Jerini AG (formerly XETRA), both of which were acquired by Bayer HealthCare AG and Shire Ltd. in two of the largest biotechnology acquisitions in German history.
My investments and involvement in Horizon Therapeutics and Evotec have been instrumental in their transformation into multi-billion-dollar companies.<\/p>","country":"","companies":[],"created_at":"2025-06-18T22:50:20.000000Z"},{"id":238,"name":"Diana Saraceni","title":"Co-Founder & General Partner","photo":{"id":1659,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1659\/diana-saraceni-panakes-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1659\/conversions\/diana-saraceni-panakes-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1659\/conversions\/diana-saraceni-panakes-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1659\/conversions\/diana-saraceni-panakes-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Panakes Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/diana-saraceni-74994\/","biography":"
Chairwoman of several national and international selection committees and juries for start-up contests including Premio Marzotto (on all editions since 2014) and European Health-tech Summit (2018); repeatedly member of Horizon 2020 final selection committees; US National Cancer Institute, 2020 and 2021 member of NCI Investor Initiatives Review Committee
Speaker at European\/US conferences on Entrepreneurship, Innovation and Life Sciences investment trends<\/p>","country":"it","companies":[],"created_at":"2025-06-27T16:57:46.000000Z"},{"id":223,"name":"Viresh Thakerar","title":"International Strategy & External Innovation Lead","photo":{"id":1652,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1652\/Headshot-Creator-for-Website---2025-06-26T033744.464.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1652\/conversions\/Headshot-Creator-for-Website---2025-06-26T033744.464-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1652\/conversions\/Headshot-Creator-for-Website---2025-06-26T033744.464-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1652\/conversions\/Headshot-Creator-for-Website---2025-06-26T033744.464-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Allergan Aesthetics (an AbbVie company)","linkedin_profile":"https:\/\/www.linkedin.com\/in\/viresh-thakerar-1b75a62\/","biography":"
Vishal's investment career spanning over two decades includes founding Recode Ventures in San Francisco and serving at leading venture firms such as Atlas Venture, Oxford Science Enterprises and Molten Ventures (fka DFJ Esprit), and also making independent private investments in ground breaking healthtech companies led by exceptional founders.
Vishal has served on the boards of over fifteen public and private health and life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by Perkin Elmer) to the world's most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European companies in digital health and AI drug discovery space such as Clue, Ieso Digital Health, Quit Genius, Zoe, Kheiron, Arctoris, Turbine, Relation Therapeutics, and AI Vivo. His portfolio of over 30 VC and angel investments makes him one of the most active investors in this space.
Vishal chairs the investment committee of Cancer Research UK seed fund, and holds similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal also serves on the advisory board of Reuben College, the newest of the Oxford University Colleges focusing on biology and artificial intelligence.<\/span>Dr. Vishal Gulati is a specialist venture capital investor backing scientists and tech founders bring their innovations to market. Prior to becoming a VC, Vishal trained as a clinician scientist at University of Oxford and Imperial College, London which gives him a rare and unique perspective on the journey of scientific discoveries all the way to commercially successful products. Vishal's investment thesis is based around the convergence of healthcare, data and engineering. Vishal's investment career spanning over two decades includes founding Recode Ventures in San Francisco and serving at leading venture firms such as Atlas Venture, Oxford Science Enterprises and Molten Ventures (fka DFJ Esprit), and also making independent private investments in ground breaking healthtech companies led by exceptional founders. Vishal has served on the boards of over fifteen public and private health and life sciences companies; from Horizon Discovery (a leading player in CRISPR gene editing now acquired by Perkin Elmer) to the world's most scalable DNA synthesis platform (Evonetix). He was an early backer of some of the pioneering European companies in digital health and AI drug discovery space such as Clue, Ieso Digital Health, Quit Genius, Zoe, Kheiron, Arctoris, Turbine, Relation Therapeutics, and AI Vivo. His portfolio of over 30 VC and angel investments makes him one of the most active investors in this space. Vishal chairs the investment committee of Cancer Research UK seed fund, and holds similar roles at The Francis Crick Institute, (KQ Labs), British Heart Foundation, Medical Research Council, and Innovate UK. Vishal also serves on the advisory board of Reuben College, the newest of the Oxford University Colleges focusing on biology and artificial intelligence.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","country":"","companies":[],"created_at":"2025-06-17T20:22:37.000000Z"},{"id":83,"name":"Tai Hah","title":"Managing Director","photo":{"id":2073,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/2073\/tai-hah-citi-europe-final.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/2073\/conversions\/tai-hah-citi-europe-final-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/2073\/conversions\/tai-hah-citi-europe-final-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/2073\/conversions\/tai-hah-citi-europe-final-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Citi","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tai-hah-3348a013\/","biography":"
Previously, I held corporate strategy and M&A roles at Verastar, a Vitruvian Partners’ portfolio company, and Grant Thornton UK LLP. I also hold a PhD in Pharmacology from the University of Liverpool’s MRC Centre for Drug Safety Science.<\/p>","country":"gb","companies":[],"created_at":"2025-07-13T05:40:11.000000Z"},{"id":122,"name":"Raf Roelands","title":"Investment Director","photo":{"id":1523,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1523\/Headshot-Creator-for-Website-(79).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1523\/conversions\/Headshot-Creator-for-Website-(79)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1523\/conversions\/Headshot-Creator-for-Website-(79)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1523\/conversions\/Headshot-Creator-for-Website-(79)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Heran Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rafroelands\/","biography":"
Awarded CBE in 2020 Queen's Birthday Honours for Services to Robotics and British Industry.
Experienced in all aspects of start-ups and scale-ups, building and leading complex technical and commercial teams teams, raising venture and development capital, and building industrial partnerships. Have worked across Medtech, Technology and FinTech sectors. Awarded UK Entrepreneur of the Year 2019 in the EYOY competition in the Industry Disruptor category and Executive of the Year 2019 by Medtech Insight.
Over last two decades I have been involved in founding, financing, listing and selling multiple business across medtech, fintech, phyiscal science technology sectors.
Passionate about starting and developing purpose-driven for-profit businesses which make a difference in people's lives.
Specialities: Purpose and people-centred leader. Building, financing and leading companies from start-up through development capital, public listing and exit. <\/p>","country":"","companies":[],"created_at":"2025-08-04T17:47:12.000000Z"},{"id":446,"name":"Ashley Seehusen","title":"Venture Partner and CEO of Sant\u00e9 Accel","photo":{"id":2055,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/2055\/ashley-seehusen-sante-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/2055\/conversions\/ashley-seehusen-sante-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/2055\/conversions\/ashley-seehusen-sante-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/2055\/conversions\/ashley-seehusen-sante-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SANTE","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ashley-seehusen-6080631\/","biography":"
My tools are innovation blending engineering, medicine, and business insights that I gained through diverse experiences and education. Since college, I have strived to learn about cardiac electrophysiology in the broadest sense—medicine, clinical trials, regulatory pathways, engineering, and the business.
I started as an electrical engineer working on a wireless EKG at MIT. Seeing how it helped patients inspired me to go to medical school and become a cardiac electrophysiologist. I’m licensed to practice medicine in Minnesota, Washington DC, Virginia, Ohio, and California.
After training at Mayo, I worked in an academic practice for 6 years. I started-up 2 companies and then spent 9 years in the medical device industry. While my passion is electrophysiology, I have worked in multiple areas of cardiology. I have been credited with 14 patents in the space, which generates $2B in revenue and touches 500K patients a year.
I am unapologetic about challenging accepted wisdom. An example includes disproving that lesions have to be transmural to get isolation around the pulmonary veins. This insight led to the understanding of High Power Short Duration Ablation, which became a core organizational competitive differentiator for St. Jude.
I am a constant learner and every year try to learn a new skill (piano and golf are examples). Because I have found the greatest innovation comes from the intersection of fields, I have sought new work experiences in adjacent fields to medical device.
Most recently, I was the Chief Strategy Officer at a state-wide $6B hospital system. This helped me better understand the challenges hospitals face and how they make decisions. It also exposed me to diverse fields like neurology and cell therapy, which could potentially help in arrhythmia care.
During my 2-years as a hospital administrator, I realized that arrhythmia care could vary depending on which doctor you saw. Much of therapy is heuristic and image based. At the same time, I was learning more about AI and thought AI would be a great way to equalize care of arrhythmias. At Neutrace, we seek to give every arrhythmia patient world-class care. <\/span><\/p>","country":"","companies":[],"created_at":"2025-04-09T23:19:57.000000Z"},{"id":120,"name":"Dennis Sardella","title":"VP - Corporate Development, Neuroscience & Diabetes","photo":{"id":1296,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1296\/Untitled-design-(23).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1296\/conversions\/Untitled-design-(23)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1296\/conversions\/Untitled-design-(23)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1296\/conversions\/Untitled-design-(23)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/msardella\/","biography":"
He was previously a consultant Gynaecological surgeon at Cambridge University Hospitals, a large teaching hospital, attached to the University of Cambridge. He is an associate lecturer st the University of Cambridge.
He has a strong background in clinical and scientific research. <\/p>","country":"","companies":[],"created_at":"2025-07-13T05:02:06.000000Z"},{"id":134,"name":"Branden Rosenhan","title":"Founding Partner","photo":{"id":1534,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1534\/Headshot-Creator-for-Website-(92).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1534\/conversions\/Headshot-Creator-for-Website-(92)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1534\/conversions\/Headshot-Creator-for-Website-(92)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1534\/conversions\/Headshot-Creator-for-Website-(92)-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"MedMountain Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/branden-d-rosenhan-m-d-b4932240\/","biography":"
I work closely with the senior management and the board of directors of our portfolio companies, providing strategic guidance, financial analysis, and operational support. I also lead the origination, due diligence, and negotiation of new investment opportunities, as well as the monitoring and exit of existing ones. Some of the recent deals I have been involved in include Salto Systems, leader in the digital transformation of access and identity management solutions, Birdie, a UK-based software for homecare providers, Twin Health, a US-based digital twin technology to help people reverse and prevent chronic metabolic diseases like type 2 diabetes, and Vizgen, a US-based company developing the next generation of spatial omics.
In addition to my investment role, I have also participated in various board and governance programs, such as the INSEAD International Directors Programme and the Harvard Business School Corporate Director Certificate, to enhance my skills and knowledge as a non-executive director.<\/p>","country":"","companies":[],"created_at":"2025-06-16T17:12:59.000000Z"},{"id":111,"name":"Andrew Pieprzyk","title":"Vice President, Strategic Development - Diagnostics, International","photo":{"id":1521,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1521\/Headshot-Creator-for-Website-(77).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1521\/conversions\/Headshot-Creator-for-Website-(77)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1521\/conversions\/Headshot-Creator-for-Website-(77)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1521\/conversions\/Headshot-Creator-for-Website-(77)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Hologic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/drewpieprzyk\/","biography":"
Focused on Venture Capital and Private Equity opportunities<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:03:17.000000Z"},{"id":138,"name":"Jayon Wang","title":"Co-Director","photo":{"id":1422,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1422\/Jayon-Wang-microport-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1422\/conversions\/Jayon-Wang-microport-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1422\/conversions\/Jayon-Wang-microport-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1422\/conversions\/Jayon-Wang-microport-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Microport Scientific Corportation Miracle Point US Incubator and Corporate Venture Investments","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jayonwang\/","biography":"
I have had the privilege of holding leadership roles in fast-growing startups and market-leading large medical device, aerospace, and technology companies.
I believe leaders, through their decisions and actions – not just their words - inspire top talents to learn more, do more, dream more, and become more; and through doing this, they achieve exceptional results. Authenticity is all about aligning what you think, what you say, and what you do.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:23:28.000000Z"},{"id":255,"name":"Tim Rea","title":"Co-Head of Early Stage","photo":{"id":1689,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1689\/tim-rea-bgf-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1689\/conversions\/tim-rea-bgf-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1689\/conversions\/tim-rea-bgf-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1689\/conversions\/tim-rea-bgf-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"BGF","linkedin_profile":"https:\/\/www.linkedin.com\/in\/tirea\/","biography":"
Dr. Yu joined Canon (formerly Toshiba) Medical Research Institute USA, Inc (CMRU) in 2013. In this role, he leads a high impact research team (10+ Ph.Ds) to identify business needs, develop innovative
solutions and deliver to the product. In 2016, the team developed world's fastest MBIR reconstruction engine and received Toshiba President's Award for this accomplishment. In 2018, the team developed world's first deep learning based CT image reconstruction product, which can significantly improve image quality.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","country":"","companies":[],"created_at":"2025-04-09T23:22:01.000000Z"},{"id":213,"name":"Diego Serrano","title":"Investor","photo":{"id":1593,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1593\/diego-serrano-sofina-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1593\/conversions\/diego-serrano-sofina-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1593\/conversions\/diego-serrano-sofina-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1593\/conversions\/diego-serrano-sofina-europe-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sofina","linkedin_profile":"https:\/\/www.linkedin.com\/in\/diegoserranocabrera\/","biography":"
<\/span><\/div>\r\n
<\/span><\/div>\r\n
I have spent my professional career as an Executive Search Consultant and Headhunter within the Medical Device & Medtech sector. I recruit Board Level Executives and MedTech professionals around the world.
Typically my customers are Early-Stage, or Growth focussed companies that want to benefit from Guided Solutions' vast Global Network and my skill in attracting talent to companies that develop disruptive technology.
I maintain a network of VCs and Angel Investors that have a particular interest in High-technology Medical Device companies. Through \"GS Capital Connect\", we attract investors who fuel this incredible sector's growth.<\/p>","country":"","companies":[],"created_at":"2025-04-09T23:09:29.000000Z"},{"id":113,"name":"Marc Ostermann","title":"VP ComEx Partnering Business","photo":{"id":1431,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1431\/marc-ostermann-tecan-europe.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1431\/conversions\/marc-ostermann-tecan-europe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1431\/conversions\/marc-ostermann-tecan-europe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1431\/conversions\/marc-ostermann-tecan-europe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Tecan","linkedin_profile":"https:\/\/www.linkedin.com\/in\/marcsostermann\/","biography":"
My passion is leading, creating and coaching winning teams, and delivering win-win solutions for our trusted partners. I have successfully built and led diverse and high-performing teams across EMEA markets and the United States, achieving above market and above plan sales growth, entering new markets, launching innovative products and services, and executing strategic partnerships and M&A deals. What motivates me is to advance healthcare by connecting technology, data, and people.<\/span><\/div>\r\n<\/div>\r\n<\/div>\r\n<\/div>","country":"ch","companies":[],"created_at":"2025-04-09T23:41:30.000000Z"},{"id":16,"name":"John Brumfield","title":"CEO","photo":{"id":1410,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1410\/john-brumfield-berlin-asia.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1410\/conversions\/john-brumfield-berlin-asia-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1410\/conversions\/john-brumfield-berlin-asia-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1410\/conversions\/john-brumfield-berlin-asia-large.webp"},"category":"innovators","roles":["C"],"company_name":"Berlin Heals","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnbrumfield\/","biography":"
Committed to global health equity, Dr. Reinöhl aims to provide broader access to life-saving technologies for underserved populations. Known for pioneering innovative clinical trials, strategic fundraising, and navigating complex regulatory landscapes, Dr. Reinöhl is a strong business leader dedicated to enhancing patient outcomes. His passion for integrating innovation and medicine positions Coramaze Technologies for exceptional growth and success.<\/p>","country":"","companies":[{"id":9,"name":"Coramaze Technologies","logo":{"id":1024,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1024\/6587fb8598781cdd3be43578_Image-9-p-500.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1024\/conversions\/6587fb8598781cdd3be43578_Image-9-p-500-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1024\/conversions\/6587fb8598781cdd3be43578_Image-9-p-500-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1024\/conversions\/6587fb8598781cdd3be43578_Image-9-p-500-large.webp"},"type":"presenter","description":"
Boardmember at the Catalan Society of Biology (Institut d'Estudis Catalans, IEC).<\/p>\r\n
Additional Competencies:
Developing new care pathways with disruptive medical technology - Special strategic projects and key healthcare partnerships - Program\/solution development & healthcare economics for value-based care - Member of the global leadership team that defines strategic company direction - Marketing & market development across a broad range of medical specialties - Assessment, acquisition, and development of new technologies & products - Product training for direct sales teams, distributors and customers globally - Development of clinical evidence and white papers for customer communication - Support of cross functionality between global marketing & sales teams - KOL advisory boards - Oversight of clinical research trials - Regulatory activities including approval, labeling, risk assessment, quality and medical device reporting with FDA - Global Health Humanitarian Programs - Company Spokesperson & Evangelist<\/p>","country":"","companies":[{"id":18,"name":"Deepsight Technology","logo":{"id":1043,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/1043\/Screenshot-2025-02-09-215931.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/1043\/conversions\/Screenshot-2025-02-09-215931-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/1043\/conversions\/Screenshot-2025-02-09-215931-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/1043\/conversions\/Screenshot-2025-02-09-215931-large.webp"},"type":"presenter","description":"